Regulator_ID	xenobiotics_id	xenobiotics_name	xenobiotics_cid	xenobiotics_synonym	Activate	Description	reference_raw	TTD ID	drugbank ID	status
REG00001	XENOBIOTIC00001	FB23	138393314	FB23; 2243736-35-6; 2-[[2,6-bis(chloranyl)-4-(3,5-dimethyl-1,2-oxazol-4-yl)phenyl]amino]benzoic acid; CHEMBL4572939; SCHEMBL23261118; BCP33227; EX-A3402; FB-23;FB 23; s6291; HY-137187; CS-0136974; A936869; 2-[[2,6-Dichloro-4-(3,5-dimethyl-4-isoxazolyl)phenyl]amino]benzoic acid; 8S3	IC50 = 60 nM	.	WO-2018157842-A1	.	.	Investigative
REG00007	XENOBIOTIC00064	MA2	.	Ethyl ester form of meclofenamic acid (MA)	.	Knockdown of METTL3 or METTL14 induced changes in mRNA m6A enrichment and altered mRNA expression of genes (e.g.,ADAM19) with critical biological functions inGSCs. Treatment with MA2, a chemical inhibitor of FTO, dramatically suppressed GSC-induced tumorigenesis and prolonged lifespan in GSC-grafted animals.	28297667	.	.	Approved
REG00006	XENOBIOTIC00064	MA2	.	Ethyl ester form of meclofenamic acid (MA)	.	Knockdown of METTL3 or METTL14 induced changes in mRNA m6A enrichment and altered mRNA expression of genes (e.g.,ADAM19) with critical biological functions inGSCs. Treatment with MA2, a chemical inhibitor of FTO, dramatically suppressed GSC-induced tumorigenesis and prolonged lifespan in GSC-grafted animals.	28297667	.	.	Approved
REG00001	XENOBIOTIC00064	MA2	.	Ethyl ester form of meclofenamic acid (MA)	.	MA2, which is a highly selective inhibitor of FTO, has a protective effect and improves the viability of HEI-OC1 cells after cisplatin treatment, and they provide new insights into potential therapeutic targets for the amelioration of cisplatin-inducedototoxicity.	29875633	.	.	Approved
REG00001	XENOBIOTIC00066	Rapamycin	5284616	Rapamune; Rapamycin (Sirolimus); AY-22989; Rapammune; sirolimusum; WY-090217; RAPA; Antibiotic AY 22989; AY 22989; UNII-W36ZG6FT64; CCRIS 9024; CHEBI:9168; SILA 9268A; W36ZG6FT64; HSDB 7284; C51H79NO13; NSC 226080; DE-109; NCGC00021305-05; DSSTox_CID_3582; DSSTox_RID_77091; DSSTox_GSID_23582; Cypher; Supralimus; Wy 090217; Perceiva; RAP; RPM; Rapamycin from Streptomyces hygroscopicus; SIIA 9268A; LCP-Siro; MS-R001; Rapamune (TN); Rapamycin (TN); Sirolimus (RAPAMUNE); Rapamycin C-7, analog 4; Sirolimus (USAN/INN); Sirolimus [USAN:BAN:INN]; Sirolimus, Rapamune,Rapamycin; Heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy; 23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine; 23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine; 23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29; 3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; Sirolimus (MTOR inhibitor)	.	The m6A changes caused by FTO influence the stability of ULK1 transcripts, likely through a YTHDF2-dependent manner.Under both basal and rapamycin-induced autophagy conditions, depletion of FTO significantly reduced the formation of GFP-LC3B puncta. The level ofp62/SQSTM1 (an autophagy substrate) was higher in FTO-knockdown cells than that in control cells. FTO specifically upregulates the ULK1 protein abundance. ULK1 mRNA undergoes m6A modification in the 3'-UTR and the m6A-marked ULK1 transcripts can further be targeted for degradation by YTHDF2.	30046135	D03LJR	DB00877	Approved
REG00015	XENOBIOTIC00068	5-FU	3385	5-Fluorouracil; 51-21-8; fluorouracil; 5-FU; Fluoroplex; Adrucil; Efudex; Carac; Fluracil; Fluoroblastin; 5-fluoropyrimidine-2,4(1H,3H)-dione; Kecimeton; Timazin; Carzonal; Efudix; Arumel; Fluril; Queroplex; Fluracilum; Ulup; 5-Fluoracil; Phthoruracil; Fluro Uracil; 5-Fluoro-2,4(1H,3H)-pyrimidinedione; Ftoruracil; Fluorouracilum; Efurix; Fluri; 5 Fluorouracil; Effluderm (free base); 5-fluoro-1H-pyrimidine-2,4-dione; Fluorouracilo; Fluroblastin; Phtoruracil; 2,4-Dihydroxy-5-fluoropyrimidine; 2,4(1H,3H)-Pyrimidinedione, 5-fluoro-;  Adrucil; Effluderm; Fluorouracile; Fluoruracil; Fluracedyl; Flurodex; Neofluor; Onkofluor; Ribofluor; Tetratogen; URF; Allergan Brand of Fluorouracil; Biosyn Brand of Fluorouracil; CSP Brand of Fluorouracil; Cinco FU; Dakota Brand of Fluorouracil; Dermatech Brand of Fluorouracil; Dermik Brandof Fluorouracil; Ferrer Brand of Fluorouracil; Fluoro Uracile ICN; Fluorouracil GRY; Fluorouracil Mononitrate; Fluorouracil Monopotassium Salt; Fluorouracil Monosodium Salt; Fluorouracil Potassium Salt; Fluorouracil Teva Brand; Fluorouracile Dakota; Fluorouracile [DCIT]; Fluorouracilo Ferrer Far; Gry Brand of Fluorouracil; Haemato Brand of Fluorouracil; Haemato fu; Hexal Brand of Fluorouracil; ICN Brand of Fluorouracil; Inhibits thymilidate synthetase; Medac Brand of Fluorouracil; Neocorp Brand of Fluorouracil; Onkoworks Brand of Fluorouracil; Ribosepharm Brand of Fluorouracil; Riemser Brand of Fluorouracil; Roche Brand of Fluorouracil; Teva Brand of Fluorouracil; F 6627; F0151; IN1335; U 8953; Adrucil (TN); Carac (TN); Dakota, Fluorouracile; Efudex (TN); Fluoro-Uracile ICN; Fluoro-uracile; Fluoro-uracilo; Fluoroplex (TN); Fluorouracil-GRY; Fluorouracilo [INN-Spanish]; Fluorouracilum [INN-Latin]; Haemato-fu; Ro 2-9757; U-8953; Ro-2-9757; Fluorouracil (JP15/USP/INN); Fluorouracil [USAN:INN:BAN:JAN]; 1-fluoro-1h-pyrimidine-2,4-dione; 2,4-Dioxo-5-fluoropryimidine; 2,4-Dioxo-5-fluoropyrimidine; 5 FU Lederle; 5 FU medac; 5 Fluorouracil biosyn; 5 HU Hexal; 5-FU (TN); 5-FU Lederle; 5-FU medac; 5-Faracil; 5-Fluor-2,4(1H,3H)-pyrimidindion; 5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]; 5-Fluor-2,4-dihydroxypyrimidin; 5-Fluor-2,4-dihydroxypyrimidin [Czech]; 5-Fluor-2,4-pyrimidindiol; 5-Fluor-2,4-pyrimidindiol [Czech]; 5-Fluoracil [German]; 5-Fluoracyl; 5-Fluoro-2,4-pyrimidinedione; 5-Fluoropyrimidin-2,4-diol; 5-Fluoropyrimidine-2,4-dione; 5-Fluorouracil-biosyn; 5-Fluoruracil; 5-Fluoruracil [German]; 5-Ftouracyl; 5-HU Hexal; 5-fluoro uracil; 5FU	.	KIAA1429 acts as an oncogenic factor inbreast cancer by regulating CDK1 in an N6-methyladenosine-independent manner.5'-fluorouracil was found to be very effective in reducing the expression of KIAA1429 andCDK1 in breast cancer.	31285549	D05LEO	DB00544	Approved
REG00006	XENOBIOTIC00069	Tamoxifen	2733526	tamoxifen; 10540-29-1; trans-Tamoxifen; Crisafeno; Soltamox; Tamoxifene; Diemon; Tamoxifenum; Tamoxifeno; Tamizam; Istubol; Tamoxen; Citofen; Oncomox; Valodex; Retaxim; Tamoxifene [INN-French]; Tamoxifenum [INN-Latin]; Tamoxifeno [INN-Spanish]; Tamoxifen (Z); Tamoxifen and its salts; Tamoxifen [INN:BAN]; ICI-46474; ICI 47699; TRANS FORM OF TAMOXIFEN; CCRIS 3275; UNII-094ZI81Y45; HSDB 6782; CHEMBL83; EINECS 234-118-0; 1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene;  Citofen; Nourytam; Novaldex; Tamone; Tamoxifeno;Tamoxifenum; Tomaxithen; Gen-Tamoxifen; Istubal (TN); Nolvadex (TN); Nolvadex-D; Novo-Tamoxifen; Pms-Tamoxifen; Tamoplex (TN); Tamoxifen (INN); Tamoxifen (TN); Trans-Tamoxifen; Valodex (TN); TAMOXIFEN (TAMOXIFEN CITRATE (54965-24-1)); Trans-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine; (Z)-1-(p-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene; (Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine; (Z)-2-(4-(1,2-diphenylbut-1-enyl)phenoxy)-N,N-dimethylethanamine; (Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine (IUPAC); (Z)-2-[4-(1,2)-DIPHENYL-1-BUTENYL)-PHENOXY]-N,N-DIMETHYLETHANAMINE; (Z)-2-[p-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine; 1-p-beta-Dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene; 1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene; 2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine; 2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine; Tamoxifen (Hormonal therapy); [3H]tamoxifen	.	METTL14 deficiency inbeta-cells induces glucose intolerance and a decrease in insulin secretion.To define the role of m6A in regulating the beta-cell function, the study generated beta-cell METTL14-specific knockout (beta-KO) mice by tamoxifen administration. beta-cell mass in beta-KO mice was related to beta-cell proliferation and also observed elevated mRNA and protein levels of Ire1-alpha and sXBP-1 in beta-KO islets.	31369074	D07KSG	DB00675	Approved
REG00012	XENOBIOTIC00073	Betaine	247	Cystadane	.	MiR-670-3p functions as the regulator of Igf2bp1 expression and plays a crucial role inparthenogenetic activation development through m6A modification. The treatment with betaine could significantly restore the m6A level.	32179813	D0XB8P	DB06756	Approved
REG00007	XENOBIOTIC00074	Simovil	54454	Cholestat; Coledis; Colemin; Corolin; Denan; Labistatin; Lipex; Lipovas; Lodales; Medipo; Nivelipol; Pantok; Rendapid; Simovil; Simvastatina; Simvastatine; Simvastatinum; Sinvacor; Sivastin; Synvinolin; Vasotenal; Zocor; Zocord; Simvast CR; Simvastatina [Spanish]; Simvastatine [French]; Simvastatinum [Latin]; MK 0733; MK 733; MK733; TNP00259; DRG-0320; KS-1113; L 644128-000U; MK-0733; MK-733; Simcard (TN); Simlup (TN); Simvacor (TN); Simvastatin & Primycin; Simvastatin, Compactin; Zocor (TN); Simvastatin [USAN:INN:BAN]; Simvastatin (JAN/USP/INN); Zocor, Simlup, Simcard, Simvacor, Simvoget, Zorced, Simvastatin; [(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate; Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester; Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester; Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,*aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester; (1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate; Butanoic acid, 2,2-dimethyl-,1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)-ethyl]-1-naphthalenyl ester, [1S-[1 alpha,3 alpha,7 beta,8 beta(2S*,4S*),-8a beta; 2,2-Dimethylbutanoic acid (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester; 2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one	.	Simvastatin induces METTL3 down-regulation in lung cancer tissues, which further influences EMT via m6A modification onEZH2 mRNA and thus inhibits the malignant progression oflung cancer.	32373962	D0H0ND	DB00641	Approved
REG00020	XENOBIOTIC00066	Rapamycin	5284616	Rapamune; Rapamycin (Sirolimus); AY-22989; Rapammune; sirolimusum; WY-090217; RAPA; Antibiotic AY 22989; AY 22989; UNII-W36ZG6FT64; CCRIS 9024; CHEBI:9168; SILA 9268A; W36ZG6FT64; HSDB 7284; C51H79NO13; NSC 226080; DE-109; NCGC00021305-05; DSSTox_CID_3582; DSSTox_RID_77091; DSSTox_GSID_23582; Cypher; Supralimus; Wy 090217; Perceiva; RAP; RPM; Rapamycin from Streptomyces hygroscopicus; SIIA 9268A; LCP-Siro; MS-R001; Rapamune (TN); Rapamycin (TN); Sirolimus (RAPAMUNE); Rapamycin C-7, analog 4; Sirolimus (USAN/INN); Sirolimus [USAN:BAN:INN]; Sirolimus, Rapamune,Rapamycin; Heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy; 23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine; 23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine; 23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29; 3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; Sirolimus (MTOR inhibitor)	.	mTOR complex 1 (mTORC1) pathway is highly activated in rbm15-deficient hepatocytes. Rapamycin treatment partially restored normal hepatic gene expression as well as the nuclear location of the transcription factor Hnf4a. Taken together, these results reveal an unexpected role of Rbm15 inliver maturation.	32518161	D03LJR	DB00877	Approved
REG00001	XENOBIOTIC00076	Meclofenamic Acid	4037	Arquel; Meclofenamate; Acide meclofenamique; Acido meclofenamico; Acidum meclofenamicum; Meclophenamic acid; CL 583; INF 4668; Acide meclofenamique [INN-French]; Acido meclofenamico [INN-Spanish]; Acidum meclofenamicum [INN-Latin]; INF-4668; Meclomen (free acid); Meclofenamic acid (USAN/INN); Meclofenamic acid [USAN:INN:BAN]; N-(2,6-Dichloro-3-methylphenyl)anthranilic acid; N-(2,6-Dichloro-m-tolyl)anthranilic acid; N-(3-Methyl-2,6-dichlorophenyl)anthranilic acid; 2-((2,6-Dichloro-3-methylphenyl)amino)benzoic acid; 2-(2,6-Dichloro-3-methylphenyl)aminobenzoic acid; 2-(2,6-dichloro-3-methylanilino)benzoic acid; 2-[(2,6-dichloro-3-methylphenyl)amino]benzoic acid	.	Genetic depletion and pharmacological inhibition of FTO dramatically attenuate leukemia stem/initiating cell self-renewal and reprogram immune response by suppressing expression of immune checkpoint genes, especiallyLILRB4. FTO inhibitors, such as rhein, meclofenamic acid (MA), MO-I-500, fluorescein, and R-2HG, can inhibitacute myeloid leukemia cell viability. CS1 and CS2 displayed a much higher efficacy in inhibiting AML cell viability.	32531268	D08IFL	DB00939	Approved
REG00001	XENOBIOTIC00078	Fluorescite	16850	Funduscein-25; Ak-fluor 10%; Ak-fluor 25%; Fluorescite	.	Genetic depletion and pharmacological inhibition of FTO dramatically attenuate leukemia stem/initiating cell self-renewal and reprogram immune response by suppressing expression of immune checkpoint genes, especiallyLILRB4. FTO inhibitors, such as rhein, meclofenamic acid (MA), MO-I-500, fluorescein, and R-2HG, can inhibitacute myeloid leukemia cell viability. CS1 and CS2 displayed a much higher efficacy in inhibiting AML cell viability.	32531268	D07FUJ	DB00693	Approved
REG00005	XENOBIOTIC00082	MPV 1440	5311068	Dexmedetomidina; Dexmedetomidinum; MPV 1440; MPV-1440; Precedex (TN); Dexmedetomidine (USAN/INN); (+)-4-((S)-alpha,2,3-Trimethylbenzyl)imidazole; 4-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole; 5-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole	.	ALKBH5 could up-regulateMALAT1 expression by demethylation. Furthermore, dexmedetomidine inhibited the expression of ALKBH5 in LPS-treated HK-2 cells. Dexmedetomidine suppressed the biological behavior of HK-2 cells treated with LPS by inhibiting the expression of ALKBH5 in vitro, which provides potential targets for the prevention and treatment of sepsis-induced kidney injury. Dexmedetomidine suppressed the biological behavior of HK-2 cells treated with LPS by inhibiting the expression of ALKBH5 in vitro, which provides potential targets for the prevention and treatment ofsepsis-induced kidney injury.	32656611	D0U3DU	DB00633	Approved
REG00007	XENOBIOTIC00066	Rapamycin	5284616	Rapamune; Rapamycin (Sirolimus); AY-22989; Rapammune; sirolimusum; WY-090217; RAPA; Antibiotic AY 22989; AY 22989; UNII-W36ZG6FT64; CCRIS 9024; CHEBI:9168; SILA 9268A; W36ZG6FT64; HSDB 7284; C51H79NO13; NSC 226080; DE-109; NCGC00021305-05; DSSTox_CID_3582; DSSTox_RID_77091; DSSTox_GSID_23582; Cypher; Supralimus; Wy 090217; Perceiva; RAP; RPM; Rapamycin from Streptomyces hygroscopicus; SIIA 9268A; LCP-Siro; MS-R001; Rapamune (TN); Rapamycin (TN); Sirolimus (RAPAMUNE); Rapamycin C-7, analog 4; Sirolimus (USAN/INN); Sirolimus [USAN:BAN:INN]; Sirolimus, Rapamune,Rapamycin; Heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy; 23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine; 23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine; 23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29; 3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; Sirolimus (MTOR inhibitor)	.	METTL3 promotes the progression ofretinoblastoma throughPI3K/AKT/mTOR pathways in vitro and in vivo. METTL3 has an impact on the PI3K-AKT-mTOR-P70S6K/4EBP1 pathway. The cell proliferation results show that the stimulatory function of METTL3 is lost after rapamycin treatment. 	33090698	D03LJR	DB00877	Approved
REG00001	XENOBIOTIC00087	Comtan	5281081	Comtan; Comtess; Entacapona; Entacaponum; Novartis brand of entacapone; Orion brand of entacapone; KB475572; OR 611; COM-998; Comtan (TN); Entacapona [INN-Spanish]; Entacapone [USAN:INN]; Entacaponum [INN-Latin]; OR-611; Stalevo (TN); Entacapone (JAN/USAN/INN); N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl) acrylamide; (2E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide; (E)-2-Cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-2-propenamide; (E)-2-cyano-3-(3,4-dihydroxy-5-nitro-phenyl)-N,N-diethyl-prop-2-enamide; (E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide; (E)-alpha-Cyano-N,N-diethyl-3,4-dihydroxy-5-nitrocinnamamide; 2-Cyano-N,N-diethyl-3-(3,4-dihydroxy-5-nitrophenyl)propenamide	.	Studies of the aberrant expression of m6A mediators inbreast cancer revealed that they were associated with different BC subtypes and functions, such as proliferation, apoptosis, stemness, the cell cycle, migration, and metastasis, through several factors and signaling pathways, such asBcl-2 and the PI3K/Akt pathway, among others. Fat mass and obesity-associated protein (FTO) was identified as the first m6A demethylase, and a series of inhibitors that target FTO were reported to have potential for the treatment of BC by inhibiting cell proliferation and promoting apoptosis.	33505967	D0J1VY	DB00494	Approved
REG00008	XENOBIOTIC00066	Rapamycin	5284616	Rapamune; Rapamycin (Sirolimus); AY-22989; Rapammune; sirolimusum; WY-090217; RAPA; Antibiotic AY 22989; AY 22989; UNII-W36ZG6FT64; CCRIS 9024; CHEBI:9168; SILA 9268A; W36ZG6FT64; HSDB 7284; C51H79NO13; NSC 226080; DE-109; NCGC00021305-05; DSSTox_CID_3582; DSSTox_RID_77091; DSSTox_GSID_23582; Cypher; Supralimus; Wy 090217; Perceiva; RAP; RPM; Rapamycin from Streptomyces hygroscopicus; SIIA 9268A; LCP-Siro; MS-R001; Rapamune (TN); Rapamycin (TN); Sirolimus (RAPAMUNE); Rapamycin C-7, analog 4; Sirolimus (USAN/INN); Sirolimus [USAN:BAN:INN]; Sirolimus, Rapamune,Rapamycin; Heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy; 23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine; 23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine; 23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29; 3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; Sirolimus (MTOR inhibitor)	.	Rapamycin inhibited FTO activity, and directly targetedeIF4G1 transcripts and mediated their expression in an m6A-dependent manner inoral squamous cell carcinoma. After FTO silencing, YTHDF2 captured eIF4G1 transcripts containing m6A, resulting in mRNA degradation and decreased expression of eIF4G1 protein, thereby promoting autophagy and reducing tumor occurrence. 	33972683	D03LJR	DB00877	Approved
REG00022	XENOBIOTIC00069	Tamoxifen	2733526	tamoxifen; 10540-29-1; trans-Tamoxifen; Crisafeno; Soltamox; Tamoxifene; Diemon; Tamoxifenum; Tamoxifeno; Tamizam; Istubol; Tamoxen; Citofen; Oncomox; Valodex; Retaxim; Tamoxifene [INN-French]; Tamoxifenum [INN-Latin]; Tamoxifeno [INN-Spanish]; Tamoxifen (Z); Tamoxifen and its salts; Tamoxifen [INN:BAN]; ICI-46474; ICI 47699; TRANS FORM OF TAMOXIFEN; CCRIS 3275; UNII-094ZI81Y45; HSDB 6782; CHEMBL83; EINECS 234-118-0; 1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene;  Citofen; Nourytam; Novaldex; Tamone; Tamoxifeno;Tamoxifenum; Tomaxithen; Gen-Tamoxifen; Istubal (TN); Nolvadex (TN); Nolvadex-D; Novo-Tamoxifen; Pms-Tamoxifen; Tamoplex (TN); Tamoxifen (INN); Tamoxifen (TN); Trans-Tamoxifen; Valodex (TN); TAMOXIFEN (TAMOXIFEN CITRATE (54965-24-1)); Trans-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine; (Z)-1-(p-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene; (Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine; (Z)-2-(4-(1,2-diphenylbut-1-enyl)phenoxy)-N,N-dimethylethanamine; (Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine (IUPAC); (Z)-2-[4-(1,2)-DIPHENYL-1-BUTENYL)-PHENOXY]-N,N-DIMETHYLETHANAMINE; (Z)-2-[p-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine; 1-p-beta-Dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene; 1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene; 2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine; 2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine; Tamoxifen (Hormonal therapy); [3H]tamoxifen	.	Direct suppression of m6A modification ofS-mu-GLT or of m6A reader YTHDC1 reduces CSR. METTL3 enzyme-catalyzed N6-methyladenosine (m6A) RNA modification drives recognition and 3' end processing of S-mu-GLT by the RNA exosome, promotingclass switch recombination and suppressing chromosomal translocations. Tamoxifen affects the role of METTL3 in B cell development.	34450044	D07KSG	DB00675	Approved
REG00001	XENOBIOTIC00092	Berberine	2353	Berberin; Umbellatine; UNII-0I8Y3P32UF; 0I8Y3P32UF; CHEBI:16118; EINECS 218-229-1; Berberal; BRN 3570374; ST055798; 9,10-Dimethoxy-2,3-(methylenedioxy)-7,8,13,13a-tetrahydroberbinium; Benzo(g)-1,3-benzodioxolo(5,6-a)quinolizinium, 5,6-dihydro-9,10-dimethoxy-; 9,10-dimethoxy-5,6-dihydro[1,3]dioxolo[4,5-g]isoquino[3,2-a]isoquinolin-7-ium; Berbamine sulphate acid; CHEMBL12089; 7,8,13,13a-tetradehydro-9,10-dimethoxy-2,3-(methylenedioxy)berbinium; BERBINIUM, 7,8,13,13a-TETRAHYDRO-9,10-DIMETHOXY-2,3-(METHYLE	.	Berberine effectively decreased m6A methylation by decreasing beta-catenin and subsequently increased FTO suggests a role of Berberine in modulating stemness and malignant behaviors incolorectal cancer.	34869024	D0W8WB	DB04115	Phase 4
REG00001	XENOBIOTIC00081	Bisantrene	5351322	Bisantrenum; CL 216942; CHEMBL25336; NSC 337766; 39C34M111K; N-[(E)-[10-[(E)-(4,5-dihydro-1H-imidazol-2-ylhydrazinylidene)methyl]anthracen-9-yl]methylideneamino]-4,5-dihydro-1H-imidazol-2-amine; 9,10-Bis((2-(4,5-dihydro-1H-imidazol-2-yl)hydrazono)methyl)anthracene; Bisantrene [INN]; Bisantrenum [INN-Latin]; 9,10-Bis(2-(4,5-dihydro-1H-imidazol-2-yl)hydrazono)methyl)anthracene; Bisantreno [INN-Spanish]; NSC337766; NSC-337766; BRN 0966309; 9,10-Anthracenedicarboxaldehyde, bis((4,5-dihydro-1H-imidazol-2-yl)hydrazone)-; 9,10-Anthracendicarbaldehyde bis(2-imidazolin-2-ylhydrazon); 9,10-Anthracenedicarboxaldehyde, bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone], dihydrochloride; SCHEMBL8906393; 9,10-bis((E)-(2-(4,5-dihydro-1H-imidazol-2-yl)hydrazono)methyl)anthracene; EX-A2382; ZINC1550957; BDBM50060768; CCG-35603; MFCD01743164; CS-6132; AS-75775; N-[(E)-[10-[(E)-(4,5-dihydro-1H-imidazol-2-ylhydrazono)methyl]-9-anthryl]methyleneamino]-4,5-dihydro-1H-imidazol-2-amine; HY-100875; 186B342; BRD-K64298650-300-01-5; 9,10-Anthracenedicarboxaldehyde Bis(2-imidazolin-2-yl-hydrazone); 9,10-Anthracenedicarbaldehyde bis(4,5-dihydro-1H-imidazol-2-ylhydrazone); anthracene-9,10 bis-carbaldehyde 4,5-dihydro-1H-imidazol-2-ylhydrazone; 9,10-anthracenedicarboxaldehyde Bis[(4,5-dihydro-1H-imidazol-2yl)hydrazone); 9,10-Anthracenedicarboxaldehyde, bis(4,5-dihydro-1H-imidazol-2-ylhydrazone),dihydrochloride; N-Anthracen-9-yl methylene N''-[(bis)4,5-dihydro-1H-imidazole-2-yl)-hydrazine; N-Anthracen-bis-9,10-ylmethylene-N''-(4,5-dihydro-1H-imidazol-2-yl)-hydrazine(bisantrene); 10-imino(4,5-dihydro-1H-2-imidazolamine)methyl-9-anthrylmethan-(4,5-dihydro-1H-2-imidazolamine)imine; Bis((4,5-dihydro-1H-imidazol-2-yl)hydrazone)-9,10-anthracenedicarboxaldehyde dihydrochloride; x N-4,5-dihydro-1H-2-imidazolamine-10-iminomethyl-9-anthrylmethanimine-4,5-dihydro-1H-2-imidazolamine (Bisantrene)	.	Genetic depletion and pharmacological inhibition of FTO dramatically attenuate leukemia stem/initiating cell self-renewal and reprogram immune response by suppressing expression of immune checkpoint genes, especiallyLILRB4. FTO inhibitors, such as rhein, meclofenamic acid (MA), MO-I-500, fluorescein, and R-2HG, can inhibitacute myeloid leukemia cell viability. CS1 and CS2 displayed a much higher efficacy in inhibiting AML cell viability.	32531268	.	.	Phase 3
REG00008	XENOBIOTIC00085	Linsitinib	11640390	Linsitinib; 867160-71-2; OSI-906; Linsitinib(OSI-906); OSI906; OSI 906; OSI-906AA; OSI-906 (Linsitinib); UNII-15A52GPT8T; Kinome_3532; ASP-7487; 3-[8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutan-1-ol; 15A52GPT8T; CHEMBL1091644; MMV676605; cis-3-[8-Amino-1-(2-phenyl-7-quinolinyl)imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutanol; C26H23N5O; cis-3-(8-amino-1-(2-phenyl-7-quinolinyl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol; Linsitinib [USAN:INN]; OSI906/Linsitinib/; Linsitinib; OSI-906	.	The m6A reader YTHDF2 stabilizedMYC mRNA specifically in cancer stem cells. Given the challenge of targeting MYC, YTHDF2 presents a therapeutic target to perturb MYC signaling in glioblastoma. The IGF1/IGF1R inhibitor linsitinib preferentially targeted YTHDF2-expressing cells, inhibiting GSC viability without affecting NSCs and impairing in vivoglioblastoma growth. YTHDF2 links RNA epitranscriptomic modifications and GSC growth, laying the foundation for the YTHDF2-MYC-IGFBP3 axis as a specific and novel therapeutic target in glioblastoma.	33023892	D01GFX	DB06075	Phase 3
REG00014	XENOBIOTIC00085	Linsitinib	11640390	Linsitinib; 867160-71-2; OSI-906; Linsitinib(OSI-906); OSI906; OSI 906; OSI-906AA; OSI-906 (Linsitinib); UNII-15A52GPT8T; Kinome_3532; ASP-7487; 3-[8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutan-1-ol; 15A52GPT8T; CHEMBL1091644; MMV676605; cis-3-[8-Amino-1-(2-phenyl-7-quinolinyl)imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutanol; C26H23N5O; cis-3-(8-amino-1-(2-phenyl-7-quinolinyl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol; Linsitinib [USAN:INN]; OSI906/Linsitinib/; Linsitinib; OSI-906	.	The m6A reader YTHDF2 stabilizedMYC mRNA specifically in cancer stem cells. Given the challenge of targeting MYC, YTHDF2 presents a therapeutic target to perturb MYC signaling in glioblastoma. The IGF1/IGF1R inhibitor linsitinib preferentially targeted YTHDF2-expressing cells, inhibiting GSC viability without affecting NSCs and impairing in vivoglioblastoma growth. YTHDF2 links RNA epitranscriptomic modifications and GSC growth, laying the foundation for the YTHDF2-MYC-IGFBP3 axis as a specific and novel therapeutic target in glioblastoma.	33023892	D01GFX	DB06075	Phase 3
REG00008	XENOBIOTIC00070	PT2385	91754484	ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A	.	YTHDF2 processed the decay of m6A-containinginterleukin 11 (IL11) and serpin family E member 2 (SERPINE2) mRNAs. YTHDF2 transcription succumbed to hypoxia-inducible factor-2-alpha (HIF-2-alpha). Administration of a HIF-2-alpha antagonist (PT2385) restored YTHDF2-programed epigenetic machinery and repressedliver cancer.	31735169	D0C9PZ	.	Phase 2
REG00001	XENOBIOTIC00080	Brequinar	57030	6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid; brequinarum [Latin]; Brequinar [INN]; Biphenquinate; 6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-methylquinoline-4-carboxylic acid; Brequinarum [INN-Latin]; UNII-5XL19F49H6; C23H15F2NO2; NSC-368390; NSC 368390; 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid; PHEZJEYUWHETKO-UHFFFAOYSA-N; Dup 785; 5XL19F49H6; 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLIC ACID; brequinarum	.	Genetic depletion and pharmacological inhibition of FTO dramatically attenuate leukemia stem/initiating cell self-renewal and reprogram immune response by suppressing expression of immune checkpoint genes, especiallyLILRB4. FTO inhibitors, such as rhein, meclofenamic acid (MA), MO-I-500, fluorescein, and R-2HG, can inhibitacute myeloid leukemia cell viability. CS1 and CS2 displayed a much higher efficacy in inhibiting AML cell viability.	32531268	D0N3XT	DB03523	Phase 2
REG00007	XENOBIOTIC00083	BEZ235	11977753	BEZ-235; S14-0511; NVP-BEZ-235; NVP-BEZ235, BEZ235; 2-(4-(2,3-dihydro-3-methyl-2-oxo-8-(quinolin-3-yl)imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile	.	METTL3 plays a carcinogenic role in human EC progression partially throughAKT signaling pathways, suggesting that METTL3 serves as a potential therapeutic target foresophageal cancer therapy. A double-effect inhibitor (BEZ235) inhibited AKT and mTOR phosphorylation and hindered the effect of METTL3 overexpression on the proliferation and migration of Eca-109 and KY-SE150 cells. 	32825955	D0VG0D	DB11651	Phase 2
REG00009	XENOBIOTIC00088	4-PBA	4775	Benzenebutyric acid; Phenyl butanoate; Phenyl butyrate; HDInhib_000004; Butanoic acid, phenyl ester; Butyric acid, phenyl ester; FR-2080; Gamma-Phenylbutyric acid; Omega-Phenylbutanoic acid; GAMMA-PHENYL-BUTYRIC ACID; Butyric acid, 4-phenyl-(8CI); 1-Phenylbutyric acid; 4-PHENYL-BUTANOIC ACID; 4-PHENYLBUTYRIC ACID; 4-Phenylbutanoic acid; 4-phenylbutans; 4-phenylbutyrate	.	Myocardial infarction (MI) is one of the leading causes of death. WTAP promoted myocardial I/R injury through promoting ER stress and cell apoptosis by regulating m6A modification ofATF4 mRNA. H/R effects on ER stress and apoptosis were all blocked by silencing of WTAP, promoted by WTAP overexpression, and ameliorated by administration of ER stress inhibitor, 4-PBA.	33819187	D0B7CH	DB06819	Phase 2
REG00007	XENOBIOTIC00089	STM2457	155167581	STM-2457; SCHEMBL22499068; GTPL11529; CHEBI:172325; EX-A5018; STM 2457; s9870; HY-134836; N-[(6-{[(cyclohexylmethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; N-[[6-[(cyclohexylmethylamino)methyl]imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxopyrido[1,2-a]pyrimidine-2-carboxamide	.	inhibition of METTL3 by STM2457 targets key stem cell populations ofacute myeloid leukaemia and reverses the AML phenotype, preventing or slowing the development of AML in re-transplantation experiments.	33902106	.	.	Preclinical
REG00001	XENOBIOTIC00086	3DZA	23190	Cc3Ado; BW-91Y78; 3DZA; 4-Amino-1-beta-D-ribofuranosyl-1H-imidazo[4,5-c]pyridine	.	Studies of the aberrant expression of m6A mediators inbreast cancer revealed that they were associated with different BC subtypes and functions, such as proliferation, apoptosis, stemness, the cell cycle, migration, and metastasis, through several factors and signaling pathways, such asBcl-2 and the PI3K/Akt pathway, among others. Fat mass and obesity-associated protein (FTO) was identified as the first m6A demethylase, and a series of inhibitors that target FTO were reported to have potential for the treatment of BC by inhibiting cell proliferation and promoting apoptosis.	33505967	D0I7TN	.	Terminated
REG00001	XENOBIOTIC00065	Beta-hydroxybutyrate	3541112	3-hydroxybutanoate; beta-hydroxybutyrate; beta-hydroxybutanoate; 3-OH butyrate; 3-OH-butyrate; beta-hydroxy-n-butyrate; UNII-FG2UN5EP9V; FG2UN5EP9V; DL-3-Hydroxybutyrate; DTXSID9040976; CHEBI:37054; BDBM50270275; Butanoic acid, 3-hydroxy-, ION(1-); Q27117026; 151-03-1	.	FTO fails to bind to its own promoter that promotes FTO expression in the hypothalamus ofhigh-fat diet-induced obese and 48-h fasting mice, suggesting a disruption of the stable expression of this gene.ketogenic diet-derived ketone body beta-hydroxybutyrate (BHB) transiently increases FTO expression in both mouse hypothalamus and cultured cells.	29771336	.	DB03568	Investigative
REG00001	XENOBIOTIC00067	FB23-2	138454779	FB23-2; 2243736-45-8; 2-((2,6-Dichloro-4-(3,5-dimethylisoxazol-4-yl)phenyl)amino)-N-hydroxybenzamide; 2-[2,6-dichloro-4-(3,5-dimethyl-1,2-oxazol-4-yl)anilino]-N-hydroxybenzamide; CHEMBL4567838; SCHEMBL23261120; BCP31164; EX-A3403; MFCD32174281; s8837; HY-127103; CS-0093102; FB23-2(FTO Demethylase inhibitor FB23-2); D81008; A936868; FB-23-2; FB 23-2; FB232; FB-232; FB 232; 2-{[2,6-Dichloro-4-(3,5-dimethyl-1,2-oxazol-4-yl)phenyl]amino}-N-hydroxybenzamide	.	FTO is a druggable target and that targeting FTO by small-molecule inhibitors(FB23 and FB23-2) holds potential to treatacute myeloid leukemia.	30991027	.	.	Investigative
REG00001	XENOBIOTIC00071	DEHP	8343	DEHP; 117-81-7; BIS(2-ETHYLHEXYL)PHTHALATE; Di(2-ethylhexyl)phthalate; Di(2-ethylhexyl) phthalate; Diethylhexyl phthalate; 2-Ethylhexyl phthalate; Di-sec-octyl phthalate; Octyl phthalate; Fleximel; Octoil; Ethylhexyl phthalate; Palatinol AH; Celluflex DOP; Vestinol AH; Bisoflex DOP; Kodaflex DOP; Staflex DOP; Truflex DOP; Flexol DOP; Vinicizer 80; Bisoflex 81; Eviplast 80; Eviplast 81; Hercoflex 260; RC plasticizer DOP; Compound 889; Witcizer 312; Platinol dop; Di-2-ethylhexyl phthalate; Nuoplaz dop; Platinol ah; Hatcol dop; Reomol dop; Pittsburgh PX-138; Sansocizer DOP; Ergoplast FDO; Monocizer DOP; Plasthall DOP; Flexol plasticizer DOP; Mollan O; Jayflex DOP; Sicol 150; Ergoplast FDO-S; Di(2-ethylhexyl)orthophthalate; Good-rite gp 264; Reomol D 79P; Bis(2-ethylhexyl) benzene-1,2-dicarboxylate; Di(ethylhexyl) phthalate; Bis(ethylhexyl) phthalate; Rcra waste number U028; Px-138; Phthalic acid dioctyl ester; NCI-C52733; Di(2-ethylhexyl) o-phthalate; Phthalic acid di(2-ethylhexyl) ester; 1,2-Benzenedicarboxylic acid, bis(2-ethylhexyl) ester; DOP; Bis(2-ethylhexyl) 1,2-benzenedicarboxylate; UNII-C42K0PH13C; Bis(2-ethylhexyl) o-phthalate; Phthalic acid, bis(2-ethylhexyl) ester; CHEBI:17747; 1,2-Benzenedicarboxylic acid bis(2-ethylhexyl) ester; Benzenedicarboxylic acid, bis(2-ethylhexyl) ester; Phthalic Acid Bis(2-ethylhexyl) Ester; Bis-(2-ethylhexyl)ester kyseliny ftalove; C42K0PH13C; 1,2-Benzenedicarboxylic acid, 1,2-bis(2-ethylhexyl) ester; DTXSID5020607; Etalon; Bis-(2-ethylhexyl)ester kyseliny ftalove [Czech]; Di-(2-ethylhexyl) phthalate; BIS-(2-ETHYLHEXYL) PHTHALATE; NCGC00091499-05; Sconamoll DOP; Diacizer DOP; Kodaflex DEHP; 15495-94-0; Etalon (plasticizer); Sansocizer R 8000; Caswell No. 392K; Dioctylphthalate; Behp; Di-2-ethylhexylphthalate; Diplast O; ESBO-D 82; Ergoplast FDO; Ergoplast FDO-S; Etalon; Phthalic acid, bis-2-ethylhexyl ester; DOF [Russian plasticizer]; SMR000777878; CCRIS 237; Ethyl hexyl phthalate; HSDB 339; Di(2-ethylhexyl) orthophthalate; Bis-(2-ethylhexyl)ester kyseliny ftalove (czech); EINECS 204-211-0; NSC 17069; Diethylhexylphthalate (Bis-(2-ethylhexyl) Phthalate); RCRA waste no. U028; Union carbide flexol 380; EPA Pesticide Chemical Code 295200; BRN 1890696; AI3-04273; DAF 68; Palatinol DOP; Polycizer DOP; Merrol DOP; Palatinol AH-L; Hatco DOP; Vinycizer 80; Di(2-ethylhexyl)phthalate (DEHP); N-Dioctyl phthalate; MFCD00009493; Corflex 400; Dioctyl phthalate, 99%; DSSTox_CID_607; 1, bis(ethylhexyl) ester; Epitope ID:140107; EC 204-211-0; WLN: 8OVR BVO8; Di(2-Ethylhexyl phthalate); DSSTox_RID_75688; DSSTox_GSID_20607; SCHEMBL20271; 14C -DEHP; 8033-53-2; MLS001333173; MLS001333174; MLS002454397; Dioctyl phthalate, >=99.5%; 1,2-Benzenedicarboxylic acid, bis-(1-ethylhexyl) ester; CHEMBL1242017; SCHEMBL21733281; HMS2233C15; HMS3374J09; AMY40790; HY-B1945; NSC17069; Tox21_400084; Bis(2-ethylhexyl)ester phthalic acid; NSC-17069; s3360; AKOS024318875; Bis(2-ethylhexyl) phthalate-[13C6]; Phthalic acid bis(2-ethylhexyl ester); MCULE-4692716107; NCGC00091499-01; NCGC00091499-02; NCGC00091499-04; NCGC00091499-06; NCGC00091499-07; CAS-117-81-7; I887; Bis(2-ethylhexyl) 1, 2-benzenedicarboxylate; CS-0014050; FT-0624576; FT-0663286; P0297; WLN: 4Y2 & 1OVR BVO1Y4 & 2; Bis(2-ethylhexyl) phthalate, Selectophore(TM); C03690; A937603; Q418492; 1,2-Benzenedicarboxylic acid bis-(1-ethylhexyl) ester; benzene-1,2-dicarboxylic acid bis(2-ethylhexyl) ester; BRD-A89471977-001-05-2; Bis(2-ethylhexyl) phthalate 100 microg/mL in Methanol; Bis(2-ethylhexyl) phthalate 5000 microg/mL in Methanol; F0001-0292; Bis(2-ethylhexyl) phthalate, SAJ first grade, >=98.0%; Bis(2-ethylhexyl) phthalate, PESTANAL(R), analytical standard; Phthalic acid, bis-2-ethylhexyl ester 10 microg/mL in Cyclohexane; Plastic additive 01, European Pharmacopoeia (EP) Reference Standard; Bis(2-ethylhexyl) phthalate, certified reference material, TraceCERT(R); Plastic additive 14, United States Pharmacopeia (USP) Reference Standard; 1,2-Benzenedicarboxylic acid, bis(2-ethylhexyl) ester, labeled with carbon-14; 50885-87-5; 82208-43-3	.	DEHP worsened testicular histology, decreased testosterone concentrations, downregulated expression of spermatogenesis inducers, enhanced oxidative stress, inhibited theNrf2-mediated antioxidant pathway, and increased apoptosis in testes. DEHP is a common environmental endocrine disrupting chemical that inducesmale reproductive disorders. Additionally, DEHP increased global levels of m6A RNA modification and altered the expression of two important RNA methylation modulator genes, FTO and YTHDC2. 	31923814	.	.	Investigative
REG00023	XENOBIOTIC00071	DEHP	8343	DEHP; 117-81-7; BIS(2-ETHYLHEXYL)PHTHALATE; Di(2-ethylhexyl)phthalate; Di(2-ethylhexyl) phthalate; Diethylhexyl phthalate; 2-Ethylhexyl phthalate; Di-sec-octyl phthalate; Octyl phthalate; Fleximel; Octoil; Ethylhexyl phthalate; Palatinol AH; Celluflex DOP; Vestinol AH; Bisoflex DOP; Kodaflex DOP; Staflex DOP; Truflex DOP; Flexol DOP; Vinicizer 80; Bisoflex 81; Eviplast 80; Eviplast 81; Hercoflex 260; RC plasticizer DOP; Compound 889; Witcizer 312; Platinol dop; Di-2-ethylhexyl phthalate; Nuoplaz dop; Platinol ah; Hatcol dop; Reomol dop; Pittsburgh PX-138; Sansocizer DOP; Ergoplast FDO; Monocizer DOP; Plasthall DOP; Flexol plasticizer DOP; Mollan O; Jayflex DOP; Sicol 150; Ergoplast FDO-S; Di(2-ethylhexyl)orthophthalate; Good-rite gp 264; Reomol D 79P; Bis(2-ethylhexyl) benzene-1,2-dicarboxylate; Di(ethylhexyl) phthalate; Bis(ethylhexyl) phthalate; Rcra waste number U028; Px-138; Phthalic acid dioctyl ester; NCI-C52733; Di(2-ethylhexyl) o-phthalate; Phthalic acid di(2-ethylhexyl) ester; 1,2-Benzenedicarboxylic acid, bis(2-ethylhexyl) ester; DOP; Bis(2-ethylhexyl) 1,2-benzenedicarboxylate; UNII-C42K0PH13C; Bis(2-ethylhexyl) o-phthalate; Phthalic acid, bis(2-ethylhexyl) ester; CHEBI:17747; 1,2-Benzenedicarboxylic acid bis(2-ethylhexyl) ester; Benzenedicarboxylic acid, bis(2-ethylhexyl) ester; Phthalic Acid Bis(2-ethylhexyl) Ester; Bis-(2-ethylhexyl)ester kyseliny ftalove; C42K0PH13C; 1,2-Benzenedicarboxylic acid, 1,2-bis(2-ethylhexyl) ester; DTXSID5020607; Etalon; Bis-(2-ethylhexyl)ester kyseliny ftalove [Czech]; Di-(2-ethylhexyl) phthalate; BIS-(2-ETHYLHEXYL) PHTHALATE; NCGC00091499-05; Sconamoll DOP; Diacizer DOP; Kodaflex DEHP; 15495-94-0; Etalon (plasticizer); Sansocizer R 8000; Caswell No. 392K; Dioctylphthalate; Behp; Di-2-ethylhexylphthalate; Diplast O; ESBO-D 82; Ergoplast FDO; Ergoplast FDO-S; Etalon; Phthalic acid, bis-2-ethylhexyl ester; DOF [Russian plasticizer]; SMR000777878; CCRIS 237; Ethyl hexyl phthalate; HSDB 339; Di(2-ethylhexyl) orthophthalate; Bis-(2-ethylhexyl)ester kyseliny ftalove (czech); EINECS 204-211-0; NSC 17069; Diethylhexylphthalate (Bis-(2-ethylhexyl) Phthalate); RCRA waste no. U028; Union carbide flexol 380; EPA Pesticide Chemical Code 295200; BRN 1890696; AI3-04273; DAF 68; Palatinol DOP; Polycizer DOP; Merrol DOP; Palatinol AH-L; Hatco DOP; Vinycizer 80; Di(2-ethylhexyl)phthalate (DEHP); N-Dioctyl phthalate; MFCD00009493; Corflex 400; Dioctyl phthalate, 99%; DSSTox_CID_607; 1, bis(ethylhexyl) ester; Epitope ID:140107; EC 204-211-0; WLN: 8OVR BVO8; Di(2-Ethylhexyl phthalate); DSSTox_RID_75688; DSSTox_GSID_20607; SCHEMBL20271; 14C -DEHP; 8033-53-2; MLS001333173; MLS001333174; MLS002454397; Dioctyl phthalate, >=99.5%; 1,2-Benzenedicarboxylic acid, bis-(1-ethylhexyl) ester; CHEMBL1242017; SCHEMBL21733281; HMS2233C15; HMS3374J09; AMY40790; HY-B1945; NSC17069; Tox21_400084; Bis(2-ethylhexyl)ester phthalic acid; NSC-17069; s3360; AKOS024318875; Bis(2-ethylhexyl) phthalate-[13C6]; Phthalic acid bis(2-ethylhexyl ester); MCULE-4692716107; NCGC00091499-01; NCGC00091499-02; NCGC00091499-04; NCGC00091499-06; NCGC00091499-07; CAS-117-81-7; I887; Bis(2-ethylhexyl) 1, 2-benzenedicarboxylate; CS-0014050; FT-0624576; FT-0663286; P0297; WLN: 4Y2 & 1OVR BVO1Y4 & 2; Bis(2-ethylhexyl) phthalate, Selectophore(TM); C03690; A937603; Q418492; 1,2-Benzenedicarboxylic acid bis-(1-ethylhexyl) ester; benzene-1,2-dicarboxylic acid bis(2-ethylhexyl) ester; BRD-A89471977-001-05-2; Bis(2-ethylhexyl) phthalate 100 microg/mL in Methanol; Bis(2-ethylhexyl) phthalate 5000 microg/mL in Methanol; F0001-0292; Bis(2-ethylhexyl) phthalate, SAJ first grade, >=98.0%; Bis(2-ethylhexyl) phthalate, PESTANAL(R), analytical standard; Phthalic acid, bis-2-ethylhexyl ester 10 microg/mL in Cyclohexane; Plastic additive 01, European Pharmacopoeia (EP) Reference Standard; Bis(2-ethylhexyl) phthalate, certified reference material, TraceCERT(R); Plastic additive 14, United States Pharmacopeia (USP) Reference Standard; 1,2-Benzenedicarboxylic acid, bis(2-ethylhexyl) ester, labeled with carbon-14; 50885-87-5; 82208-43-3	.	DEHP worsened testicular histology, decreased testosterone concentrations, downregulated expression of spermatogenesis inducers, enhanced oxidative stress, inhibited theNrf2-mediated antioxidant pathway, and increased apoptosis in testes. DEHP is a common environmental endocrine disrupting chemical that inducesmale reproductive disorders. Additionally, DEHP increased global levels of m6A RNA modification and altered the expression of two important RNA methylation modulator genes, FTO and YTHDC2. 	31923814	.	.	Investigative
REG00007	XENOBIOTIC00072	Cycloleucine	2901	1-Aminocyclopentanecarboxylic acid; 52-52-8; 1-Aminocyclopentane-1-carboxylic acid; Cycloleucin; 1-Amino-1-cyclopentanecarboxylic acid; 1-Amino-1-carboxycyclopentane; 1-Amino-cyclopentanecarboxylic acid; CYCLO-LEUCINE; Cyclopentanecarboxylic acid, 1-amino-; NSC 1026; CB 1639; X 201; UNII-0TQU7668EI; 1-Aminocyclopentanecarboxylate; HSDB 5195; WR 14,997; NSC1026; 1-amino cyclopentane carboxylic acid; EINECS 200-144-6; BRN 0636626; aminocyclopentanecarboxylic acid; Cyclopentanecarboxylic acid, 1-amino-, L-; AI3-26442	.	METTL3-mediated m6A RNA methylation modulatesuveal melanoma cell proliferation, migration, and invasion by targetingc-Met. Cycloleucine (Cyc) was used to block m6 A methylation in UM cells. 	32017066	D0P0GT	DB04620	Investigative
REG00001	XENOBIOTIC00075	Rhein	10168	Monorhein; Rheic acid; Rhubarb Yellow; Cassic acid; 4,5-Dihydroxyanthraquinone-2-carboxylic acid; Chrysazin-3-carboxylic acid; 4,5-dihydroxy-9,10-dioxo-9,10-dihydroanthracene-2-carboxylic acid; NSC 38629; Rheinic acid; 1,8-Dihydroxyanthraquinone-3-carboxylic acid; dipropionyl rhein; 1,8-Dihydroxy-3-carboxyanthraquinone; UNII-YM64C2P6UX; Rhein(Monorhein); 2-Anthracenecarboxylic acid, 9,10-dihydro-4,5-dihydroxy-9,10-dioxo-; CCRIS 5129; 9,10-Dihydro-4,5-dihydroxy-9,10-dioxo-2-anthracenecarboxylic acid; C15H8O6	.	Genetic depletion and pharmacological inhibition of FTO dramatically attenuate leukemia stem/initiating cell self-renewal and reprogram immune response by suppressing expression of immune checkpoint genes, especiallyLILRB4. FTO inhibitors, such as rhein, meclofenamic acid (MA), MO-I-500, fluorescein, and R-2HG, can inhibitacute myeloid leukemia cell viability. CS1 and CS2 displayed a much higher efficacy in inhibiting AML cell viability.	32531268	D0M2TY	DB13174	Investigative
REG00001	XENOBIOTIC00077	MO-I-500	.	.	.	Genetic depletion and pharmacological inhibition of FTO dramatically attenuate leukemia stem/initiating cell self-renewal and reprogram immune response by suppressing expression of immune checkpoint genes, especiallyLILRB4. FTO inhibitors, such as rhein, meclofenamic acid (MA), MO-I-500, fluorescein, and R-2HG, can inhibitacute myeloid leukemia cell viability. CS1 and CS2 displayed a much higher efficacy in inhibiting AML cell viability.	32531268	.	.	Investigative
REG00001	XENOBIOTIC00079	R-2HG 	439391	(R)-2-Hydroxypentanedioic acid; 13095-47-1; D-2-Hydroxyglutaric acid; (R)-2-hydroxyglutaric acid; (R)-Hydroxyglutarate; (R)-2-hydroxyglutarate; Pentanedioic acid, 2-hydroxy-, (2R)-; CHEMBL1614745; CHEBI:32796; D-2-Hydroxyglutarate; Glutaric acid, 2-hydroxy-; d-alpha-hydroxyglutaric acid; D-Hydroxyglutarate; 2HG; D-a-Hydroxyglutarate; 2-hydroxy-D-Glutarate; (R)-a-Hydroxyglutarate; delta-2-Hydroxyglutarate; D-a-Hydroxyglutaric acid; 2-hydroxy-delta-Glutarate; D-; A-Hydroxyglutaric acid; (2R)-hydroxyglutaric acid; 2-hydroxy-D-Glutaric acid; (R)-alpha-Hydroxyglutarate; delta-alpha-Hydroxyglutarate; SCHEMBL8032; (R)-a-Hydroxyglutaric acid; delta-2-Hydroxyglutaric acid; (R)-2-hydroxy-Pentanedioate; 2-hydroxy-delta-Glutaric acid; (R)-alpha-Hydroxyglutaric acid; delta-alpha-Hydroxyglutaric acid; (R)-2-hydroxy-Pentanedioic acid; DTXSID80897218; ZINC402968; BDBM50361471; AKOS027325193; FD21404; BS-50252; HY-113038; CS-0059411; C01087; 93397C3E-3CE9-4FEA-A2ED-8F6FA59A1FEA; Q27104222; Z2217110365; 636-67-9	.	Genetic depletion and pharmacological inhibition of FTO dramatically attenuate leukemia stem/initiating cell self-renewal and reprogram immune response by suppressing expression of immune checkpoint genes, especiallyLILRB4. FTO inhibitors, such as rhein, meclofenamic acid (MA), MO-I-500, fluorescein, and R-2HG, can inhibitacute myeloid leukemia cell viability. CS1 and CS2 displayed a much higher efficacy in inhibiting AML cell viability.	32531268	.	.	Investigative
REG00001	XENOBIOTIC00084	Mehp	20393	Mehp; Mono(2-ethylhexyl) phthalate; PHTHALIC ACID MONO-2-ETHYLHEXYL ESTER; Mono(2-ethylhexyl)phthalate; 2-Ethylhexyl hydrogen phthalate; Monoethylhexyl phthalate; MONO-2-ETHYLHEXYL PHTHALATE; Mono-(2-ethylhexyl)phthalate; 2-(2-ethylhexoxycarbonyl)benzoic acid; (2-Ethylhexyl) hydrogen phthalate; 1,2-Benzenedicarboxylic acid, mono(2-ethylhexyl) ester; 2-{[(2-ethylhexyl)oxy]carbonyl}benzoic acid; Monoethylhexyl phthalic acid; Phthalic acid, mono-(2-ethylhexyl) ester; CHEBI:17243; PHTHALIC ACID MONOOCTYL ESTER; Phthalic acid mono-2-ethylhexylester; Phthalic acid, mono-2-ethylhexyl ester; NCGC00090773-04; 1276197-22-8; BAR 1; Phthalate, mono(2-ethylhexyl); CCRIS 1742; 2-([(2-Ethylhexyl)oxy]carbonyl)benzoic acid; rac Mono(ethylhexyl) Phthalate-d4; EINECS 224-477-1; mono(ethylhexyl) phthalate; mono-ethylhexyl; Mono-(2-ethylhexyl) phthalate; rac Mono(ethylhexyl) Phthalate; monoethylhexylphthalate; mono-ethylhexylphthalate; DSSTox_CID_5680; Phthalic acid, 2-ethylhexyl ester (6CI,7CI); DSSTox_RID_77879; DSSTox_GSID_25680; phthalicacidmonoethylhexylester; phthalicacid,2-ethylhexylester; SCHEMBL472689; mono-(2-ethyl)hexyl phthalate; PHTHALICACIDMONOETHYLHEXYL; CHEMBL1867438; DTXSID2025680; Monoethylhexyl phthalate (mEHP); phthalic acid, 2-ethylhexyl ester; Mono-(2-ethylhexyl) phthalate-d4; ACT03365; Tox21_400076; MFCD00041500; AKOS015902975; CS-W019178; HY-W018392; 2-(2-ethylhexyloxycarbonyl)benzoic acid; PHTHALICACIDMONO-2-ETHYLEXYLESTER; NCGC00090773-01; NCGC00090773-02; NCGC00090773-03; NCGC00090773-05; NCGC00090773-06; DS-16446; CAS-4376-20-9; DB-007821; 2-[(2S)-2-ethylhexoxy]carbonylbenzoic acid; FT-0600523; Phthalic acid mono-2-ethylhexyl ester liquid; Phthalic acid mono-2-ethylhexyl ester, 97%; W6291; C03343; Phthalic acid hydrogen 1-(2-ethylhexyl) ester; 2-([(2-Ethylhexyl)oxy]carbonyl)benzoic acid #; A826416; Phthalic acid 1-hydrogen 2-(2-ethylhexyl) ester; phthalic acid mono-2-ethylhexyl ester, AldrichCPR; 1,2-benzenedicarboxylicacid,mono(2-ethylhexyl)ester; BRD-A18246003-001-01-1; Q26841225; 1,2-Benzenedicarboxylic acid, mono(2-ethylhexyl) ester (9CI); Phthalic acid, mono-2-ethylhexyl ester 100 microg/mL in Acetonitrile	.	The inhibition of FTO-mediated up-regulation of m6A could be involved in MEHP-inducedLeydig cell apoptosis.	33010548	.	.	Investigative
REG00001	XENOBIOTIC00072	Cycloleucine	2901	1-Aminocyclopentanecarboxylic acid; 52-52-8; 1-Aminocyclopentane-1-carboxylic acid; Cycloleucin; 1-Amino-1-cyclopentanecarboxylic acid; 1-Amino-1-carboxycyclopentane; 1-Amino-cyclopentanecarboxylic acid; CYCLO-LEUCINE; Cyclopentanecarboxylic acid, 1-amino-; NSC 1026; CB 1639; X 201; UNII-0TQU7668EI; 1-Aminocyclopentanecarboxylate; HSDB 5195; WR 14,997; NSC1026; 1-amino cyclopentane carboxylic acid; EINECS 200-144-6; BRN 0636626; aminocyclopentanecarboxylic acid; Cyclopentanecarboxylic acid, 1-amino-, L-; AI3-26442	.	Studies of the aberrant expression of m6A mediators inbreast cancer revealed that they were associated with different BC subtypes and functions, such as proliferation, apoptosis, stemness, the cell cycle, migration, and metastasis, through several factors and signaling pathways, such asBcl-2 and the PI3K/Akt pathway, among others. Fat mass and obesity-associated protein (FTO) was identified as the first m6A demethylase, and a series of inhibitors that target FTO were reported to have potential for the treatment of BC by inhibiting cell proliferation and promoting apoptosis.	33505967	D0P0GT	DB04620	Investigative
REG00001	XENOBIOTIC00090	4-amino-3-quinolinecarboxylic acid	11651286	4-amino-3-quinolinecarboxylic acid; 4-Amino-quinoline-3-carboxylic acid; 3-Quinolinecarboxylicacid, 4-amino-; 4-aminoquinoline-3-carboxylic; SCHEMBL436714; DTXSID10470018; BBL031107; MFCD08705653; STK660776; ZINC14982158; AKOS002326679; MCULE-8408161492; SB67440; VS-10248; DB-081679; BB 0222277; CS-0248109; FT-0748901; Y9812; EN300-39148; J-514466; F2183-0223; Z398556732	.	Inhibition of m6A RNA demethylation by small-molecule drugs, as presented here, has therapeutic potential and provides tools for the identification of disease-modifying m6A RNAs inneurogenesis and neuroregeneration. Small-molecule inhibitors of the RNA m6A demethylases FTO potently support the survival of dopamine neurons.	33926120	.	.	Investigative
REG00024	XENOBIOTIC00077	MO-I-500	.	.	.	Perturbed m6A signaling can be contributing toAlzheimer's disease pathogenesis, likely by compromising astrocyte bioenergetics. MO-I-500, a novel pharmacological inhibitor of FTO, can strongly reduce the adverse effects of STZ. STZ-treated astrocytes expressed significantly higher levels of m6A demethylase FTO and m6A reader YTHDF1. 	34491720	.	.	Investigative
REG00007	XENOBIOTIC00091	AdoHcy	439155	S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; S-adenosyl-L-homocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH; S-Adenosylhomocysteine; S-Adenosyl-L-Homocysteine	.	Mettl3 inhibitor, S-adenosylhomocysteine promoted the apoptosis and autophagy of chondrocytes with inflammation in vitro and aggravated the degeneration of chondrocytes and subchondral bone in monosodium iodoacetate (MIA) inducedtemporomandibular joint osteoarthritis mice in vivo. Bcl2 protein interacted with Beclin1 protein in chondrocytes induced by TNF-alpha stimulation. Mettl3 inhibits the apoptosis and autophagy of chondrocytes in inflammation through m6A/Ythdf1/Bcl2 signal axis which provides promising therapeutic strategy fortemporomandibular joint osteoarthritis.	34530171	D09CLP	DB01752	Investigative
REG00024	XENOBIOTIC00091	AdoHcy	439155	S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; S-adenosyl-L-homocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH; S-Adenosylhomocysteine; S-Adenosyl-L-Homocysteine	.	Mettl3 inhibitor, S-adenosylhomocysteine promoted the apoptosis and autophagy of chondrocytes with inflammation in vitro and aggravated the degeneration of chondrocytes and subchondral bone in monosodium iodoacetate (MIA) inducedtemporomandibular joint osteoarthritis mice in vivo. Bcl2 protein interacted with Beclin1 protein in chondrocytes induced by TNF-alpha stimulation. Mettl3 inhibits the apoptosis and autophagy of chondrocytes in inflammation through m6A/Ythdf1/Bcl2 signal axis which provides promising therapeutic strategy fortemporomandibular joint osteoarthritis.	34530171	D09CLP	DB01752	Investigative
REG00005	XENOBIOTIC00093	IOX1	459617	5852-78-8; 8-Hydroxyquinoline-5-Carboxylic Acid; 8-Hydroxy-5-quinolinecarboxylic acid; 5-Carboxy-8-hydroxyquinoline; IOX 1; UNII-JM015YQC1C; IOX-1; 5-carboxy-8HQ; 5-Quinolinecarboxylic acid, 8-hydroxy-; JM015YQC1C; CHEMBL1230640; 4bio; 4jht; 8XQ; 4ie4; AC1LA0UV; MLS002729056; GTPL8230; SCHEMBL6068195; KS-00000PPH; CHEBI:93239; CTK1E0142; DTXSID20207236; AOB6499; JGRPKOGHYBAVMW-UHFFFAOYSA-N; MolPort-006-673-354; HMS3653E21; ZINC5933707; BCP16996; s7234; BDBM50396018; 2184AH; IOX1, > AKOS016371793	.	IOX1, which is an inhibitor of ALKBH5, was loaded on HSSS to form HSSS-I, which could effectively ameliorate cardiac dysfunction inacute myocardial infarction. The surface-modified bioengineered ferritin nanocage targeted the dying cells in the infarct area under the guidance ofScarf1. These cells were then phagocytosed through recognition of their TfR1 receptor.	34879293	D0X5US	.	Investigative
REG00001	XENOBIOTIC00002	(Z)-3-(3,4-dihydroxy-5-nitrophenyl)-2-pyrazin-2-ylprop-2-enenitrile	137283544	CHEMBL4448030; SCHEMBL20100848	IC50 <= 250 nM	.	US-20180118665-A1	.	.	.
REG00001	XENOBIOTIC00003	5-[(Z)-1-cyano-2-(3,4-dihydroxy-5-nitrophenyl)ethenyl]pyrazine-2-carboxylic acid	140868191	CHEMBL4563060; SCHEMBL21932996	IC50 <= 300 nM	.	US-20180118665-A1	.	.	.
REG00001	XENOBIOTIC00004	2,6-dichloro-4-(3,5-dimethyl-1,2-oxazol-4-yl)-N-[2-(2H-tetrazol-5-yl)phenyl]aniline	148272910	CHEMBL4532629	IC50 = 400 nM	.	WO-2018157842-A1	.	.	.
REG00001	XENOBIOTIC00005	(Z)-3-(3,4-dihydroxy-5-nitrophenyl)-2-pyrimidin-4-ylprop-2-enenitrile	137283546	CHEMBL4527360; SCHEMBL20100853	IC50 <= 500 nM	.	US-20180118665-A1	.	.	.
REG00001	XENOBIOTIC00006	(Z)-3-amino-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide	134463668	CHEMBL4567049; SCHEMBL20100829	IC50 <= 500 nM	.	US-20180118665-A1	.	.	.
REG00001	XENOBIOTIC00007	(Z)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-3-hydroxy-N-(1,3-thiazol-2-yl)prop-2-enamide	134463699	CHEMBL4435468; SCHEMBL20100862	IC50 <= 500 nM	.	US-20180118665-A1	.	.	.
REG00001	XENOBIOTIC00008	(Z)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-3-hydroxyprop-2-enamide	134463661	CHEMBL4461072; SCHEMBL20100822	IC50 <= 500 nM	.	US-20180118665-A1	.	.	.
REG00001	XENOBIOTIC00009	(E)-3-(3,4-dihydroxy-5-nitrophenyl)-3-hydroxy-2-pyrimidin-4-ylprop-2-enenitrile	137283530	CHEMBL4467308; SCHEMBL20100828	IC50 <= 500 nM	.	US-20180118665-A1	.	.	.
REG00001	XENOBIOTIC00010	(E)-3-(3,4-dihydroxy-5-nitrophenyl)-3-hydroxy-2-pyrazin-2-ylprop-2-enenitrile	137283525	CHEMBL4529597; SCHEMBL20100823	IC50 <= 500 nM	.	US-20180118665-A1	.	.	.
REG00001	XENOBIOTIC00011	2-[2,6-Dichloro-4-(3,5-dihydroxyphenyl)anilino]benzoic acid	153457709	CHEMBL4563024	IC50 = 700 nM	.	WO-2018157842-A1	.	.	.
REG00001	XENOBIOTIC00012	(Z)-2-(azetidine-1-carbonyl)-3-(3,4-dihydroxy-5-nitrophenyl)-3-hydroxyprop-2-enenitrile	134463713	CHEMBL4458750; SCHEMBL20100880	IC50 <= 750 nM	.	US-20180118665-A1	.	.	.
REG00001	XENOBIOTIC00013	5-[(E)-1-cyano-2-(3,4-dihydroxy-5-nitrophenyl)-2-hydroxyethenyl]pyrazine-2-carboxylic acid	140868246	CHEMBL4463923; SCHEMBL21933009	IC50 <= 750 nM	.	US-20180118665-A1	.	.	.
REG00001	XENOBIOTIC00014	(Z)-3-amino-3-(3,4-dihydroxy-5-nitrophenyl)-2-(piperidine-1-carbonyl)prop-2-enenitrile	134463716	CHEMBL4590326; SCHEMBL20100883	IC50 <= 750 nM	.	US-20180118665-A1	.	.	.
REG00001	XENOBIOTIC00015	(E)-3-(3,4-dihydroxy-5-nitrophenyl)-3-hydroxy-2-pyridin-2-ylprop-2-enenitrile	137283547	CHEMBL4569935; SCHEMBL20100854	IC50 <= 750 nM	.	US-20180118665-A1	.	.	.
REG00002	XENOBIOTIC00016	1-(Benzenesulfonyl)-3-phenylindole-4,5-dione	132251303	CHEMBL4075458; SCHEMBL19737490; BDBM50270003	Ki = 12.8 nM	.	29313684	.	.	.
REG00002	XENOBIOTIC00017	1-(Benzenesulfonyl)-7-(4-methoxyphenyl)sulfanyl-3-phenylindole-4,5-dione	137635149	CHEMBL4064932; BDBM50269995	Ki = 15 nM	.	29313684	.	.	.
REG00002	XENOBIOTIC00018	1-(Benzenesulfonyl)-7-(4-methoxyphenyl)-3-phenylindole-4,5-dione	137652621	CHEMBL4095060; SCHEMBL22130724; BDBM50269992	Ki = 41 nM	.	29313684	.	.	.
REG00002	XENOBIOTIC00019	1-(4-Fluorophenyl)sulfonyl-3-phenylindole-4,5-dione	137659568	CHEMBL4100171; SCHEMBL21222486; BDBM50269999	Ki = 48 nM	.	29313684	.	.	.
REG00002	XENOBIOTIC00020	Dihydrotanshinone I	11425923	Dihydrotanshinone I; 87205-99-0; 15,16-dihydrotanshinone I; UNII-562G9360V6; (-)-Dihydrotanshinone I; (1R)-1,6-dimethyl-1,2-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione; DIHYDROTANSHINONE; 562G9360V6; DihydrotanshinoneI; Dihydrotanshinone-I; Tanshinone I, dihydro-; SR-05000002191; HSDB 8105; DHTS; 4m0e; CHEMBL227075; SCHEMBL13049977; DTXSID20236187; CHEBI:149872; HY-N0360; ZINC2585546; BDBM50423877; MFCD28016070; s9020; AKOS032962078; CCG-208567; Dihydrotanshinone I, >=98% (HPLC); NCGC00163651-01; NCGC00163651-06; D5379; N1844; A862726; SR-05000002191-2; SR-05000002191-3; Q21099654; (1R)-1,6-dimethyl-1,2-dihydrophenanthro[1,2-b]furan-10,11-dione; (R)-1,6-dimethyl-1,2-dihydrophenanthro[1,2-b]furan-10,11-dione; (-)-1,2-Dihydro-1,6-dimethylphenanthro[1,2-b]furan-10,11-dione;1,6-Dimethyl-1,2,10,11-tetrahydrophenanthro[1,2-b]furan-10,11-dione;4,17-Dimethyl-15-oxagona-1,3,5(10),6,8,13-hexene-11,12-dione;15,16-Dihydrotanshine I;1,6-DiMethyl-1,2-dihydrophenanthro[1,2-b]furan-10,11-dione	Ki = 50 nM	.	29313684	.	.	.
REG00002	XENOBIOTIC00021	1-(Benzenesulfonyl)-7-(3-methoxyphenyl)-3-phenylindole-4,5-dione	137657529	CHEMBL4105230; BDBM50269991	Ki = 55 nM	.	29313684	.	.	.
REG00002	XENOBIOTIC00022	1-Methylsulfonyl-3-phenylindole-4,5-dione	132251294	CHEMBL4073526; SCHEMBL19737481; BDBM50270012	Ki = 56 nM	.	29313684	.	.	.
REG00002	XENOBIOTIC00023	N-[4-(4,5-dioxo-3-phenylindol-1-yl)sulfonylphenyl]acetamide	137655418	CHEMBL4094161; SCHEMBL22130699; BDBM50269996	Ki = 81 nM	.	29313684	.	.	.
REG00002	XENOBIOTIC00024	1-(3-Nitrophenyl)sulfonyl-3-phenylindole-4,5-dione	132251198	CHEMBL4081086; SCHEMBL19737379; BDBM50270013	Ki > 100 nM	.	29313684	.	.	.
REG00002	XENOBIOTIC00025	1-(Benzenesulfonyl)-7-(4-nitrophenyl)-3-phenylindole-4,5-dione	137633625	CHEMBL4067653; BDBM50270007	Ki > 100 nM	.	29313684	.	.	.
REG00002	XENOBIOTIC00026	1-(3-Fluorophenyl)sulfonyl-3-phenylindole-4,5-dione	132251245	CHEMBL4092808; SCHEMBL19737426; BDBM50269997	Ki > 100 nM	.	29313684	.	.	.
REG00002	XENOBIOTIC00027	1-(Benzenesulfonyl)-3-[4-(dimethylamino)phenyl]indole-4,5-dione	132251374	CHEMBL4076484; SCHEMBL19737562; BDBM50270014	Ki > 100 nM	.	29313684	.	.	.
REG00002	XENOBIOTIC00028	1-(Benzenesulfonyl)-3,7-diphenylindole-4,5-dione	137657577	CHEMBL4102819; SCHEMBL21222570; BDBM50269994	Ki > 100 nM	.	29313684	.	.	.
REG00002	XENOBIOTIC00029	1-(Benzenesulfonyl)-7-methyl-3-phenylindole-4,5-dione	137638771	CHEMBL4070465; SCHEMBL22130661; BDBM50269990	Ki > 200 nM	.	29313684	.	.	.
REG00002	XENOBIOTIC00030	1-(Benzenesulfonyl)-3-(3-methoxyphenyl)indole-4,5-dione	132251300	CHEMBL4075620; SCHEMBL19737487; BDBM50270001	Ki > 200 nM	.	29313684	.	.	.
REG00002	XENOBIOTIC00031	1-(Benzenesulfonyl)-3-(4-methoxyphenyl)indole-4,5-dione	132251295	CHEMBL4077265; SCHEMBL19737482; BDBM50270002	Ki > 200 nM	.	29313684	.	.	.
REG00002	XENOBIOTIC00032	4-(Benzenesulfonyl)-6-phenyl-4-azatetracyclo[9.2.2.02,10.03,7]pentadeca-2(10),3(7),5,12-tetraene-8,9-dione	132251354	CHEMBL4073683; SCHEMBL19737542; BDBM50270004	Ki > 300 nM	.	29313684	.	.	.
REG00002	XENOBIOTIC00033	CMLD-2	16746438	958843-91-9; 5,7-dimethoxy-8-(1-(4-methoxyphenyl)-3-oxo-3-(pyrrolidin-1-yl)propyl)-4-phenyl-2H-chromen-2-one; CMLD-2; MLS000879470; SMR000465530; 5,7-dimethoxy-8-[1-(4-methoxyphenyl)-3-oxo-3-pyrrolidin-1-ylpropyl]-4-phenylchromen-2-one; KUC101379N; 5,7-dimethoxy-8-[1-(4-methoxyphenyl)-3-oxo-3-(pyrrolidin-1-yl)propyl]-4-phenyl-2H-chromen-2-one; CHEMBL1499653; SCHEMBL20928323; BDBM50746; cid_16746438; HMS2210J15; AKOS037647737; NCGC00166452-01; AS-74611; HY-124828; CS-0087821; W15560; 8-[3-keto-1-(4-methoxyphenyl)-3-pyrrolidino-propyl]-5,7-dimethoxy-4-phenyl-coumarin; 5,7-dimethoxy-8-[1-(4-methoxyphenyl)-3-oxidanylidene-3-pyrrolidin-1-yl-propyl]-4-phenyl-chromen-2-one; 5,7-dimethoxy-8-[1-(4-methoxyphenyl)-3-oxo-3-(1-pyrrolidinyl)propyl]-4-phenyl-1-benzopyran-2-one	Ki = 350 nM	.	28587461	.	.	.
REG00002	XENOBIOTIC00034	2-Amino-6-[2-(3,4-dihydroxyphenyl)-2-oxoethyl]sulfanyl-4-[4-(phenoxymethyl)phenyl]pyridine-3,5-dicarbonitrile	137637060	CHEMBL4061748	IC50 = 380 nM	.	28587461	.	.	.
REG00002	XENOBIOTIC00035	3-(5,7-dimethoxy-2-oxo-4-phenylchromen-8-yl)-N,N-diethyl-3-(4-methoxyphenyl)propanamide	24868003	CHEMBL1522581; NCGC00166661-01	Ki = 570 nM	.	28587461	.	.	.
REG00002	XENOBIOTIC00036	3-(5,7-dimethoxy-2-oxo-4-phenylchromen-8-yl)-N,N-diethyl-3-(3,4,5-trimethoxyphenyl)propanamide	16746297	MLS000879482; SMR000465537; KUC101391N; CHEMBL1330249; SCHEMBL20928107; BDBM50745; cid_16746297; HMS2220E05; HMS3331O06; NCGC00166568-01; 3-(5,7-dimethoxy-2-oxidanylidene-4-phenyl-chromen-8-yl)-N,N-diethyl-3-(3,4,5-trimethoxyphenyl)propanamide; 3-(5,7-dimethoxy-2-oxo-4-phenyl-1-benzopyran-8-yl)-N,N-diethyl-3-(3,4,5-trimethoxyphenyl)propanamide; 3-(5,7-dimethoxy-2-oxo-4-phenylchromen-8-yl)-N,N-diethyl-3-(3,4,5-trimethoxyphenyl)propanamide; N,N-diethyl-3-(2-keto-5,7-dimethoxy-4-phenyl-chromen-8-yl)-3-(3,4,5-trimethoxyphenyl)propionamide	Ki = 590 nM	.	28587461	.	.	.
REG00002	XENOBIOTIC00037	8-[3-Keto-1-(4-methoxyphenyl)-3-morpholino-propyl]-5,7-dimethoxy-4-phenyl-coumarin	16746461	MLS000879474; SMR000465528; KUC101375N; CHEMBL1390568; BDBM51309; cid_16746461; HMS2212O19; HMS3348C12; NCGC00166769-01; 5,7-dimethoxy-8-[1-(4-methoxyphenyl)-3-morpholin-4-yl-3-oxopropyl]-4-phenylchromen-2-one; 8-[3-keto-1-(4-methoxyphenyl)-3-morpholino-propyl]-5,7-dimethoxy-4-phenyl-coumarin; 5,7-dimethoxy-8-[1-(4-methoxyphenyl)-3-(4-morpholinyl)-3-oxopropyl]-4-phenyl-1-benzopyran-2-one; 5,7-dimethoxy-8-[1-(4-methoxyphenyl)-3-morpholin-4-yl-3-oxidanylidene-propyl]-4-phenyl-chromen-2-one	Ki = 800 nM	.	28587461	.	.	.
REG00005	XENOBIOTIC00038	Citric acid	311	citric acid; 77-92-9; 2-hydroxypropane-1,2,3-tricarboxylic acid; Citric acid, anhydrous; Anhydrous citric acid; Citro; Aciletten; Citretten; Chemfill; Hydrocerol A; 1,2,3-Propanetricarboxylic acid, 2-hydroxy-; 2-hydroxy-1,2,3-propanetricarboxylic acid; Citric acid anhydrous; Kyselina citronova; 2-Hydroxytricarballylic acid; Caswell No. 221C; F 0001 (polycarboxylic acid); 3-Carboxy-3-hydroxypentane-1,5-dioic acid; 2-Hydroxypropanetricarboxylic acid; FEMA No. 2306; FEMA Number 2306; K-Lyte; Kyselina citronova [Czech]; K-Lyte DS; CCRIS 3292; HSDB 911; EPA Pesticide Chemical Code 021801; Uro-trainer; AI3-06286; UNII-XF417D3PSL; Suby G; NSC 30279; NSC 626579; BRN 0782061; Citric acid,anhydrous; MFCD00011669; CHEMBL1261; XF417D3PSL; Kyselina 2-hydroxy-1,2,3-propantrikarbonova [Czech]; Kyselina 2-hydroxy-1,2,3-propantrikarbonova; CHEBI:30769; .beta.-Hydroxytricarballylic acid; citr; NSC30279; NSC-30279; NSC626579; NSC-626579; Citric acid, 99%; NCGC00090954-03; E330; DSSTox_CID_332; E 330; beta-Hydroxytricarballylic acid; CITRATE ANION; DSSTox_RID_75520; DSSTox_GSID_20332; 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, homopolymer; Citric acid [USAN:JAN]; CAS-77-92-9; 141633-96-7; 1,3-Propanetricarboxylic acid, 2-hydroxy-; NSC-112226; EINECS 201-069-1; Citraclean; Citronensaeure; Acidum citricum; citric-acid; Citricum acidum; Citric acid bp; Anhydrous citrate; 2fwp; 4aci; 4nrm; H3cit; Citric acid, anhydrous [USP:JAN]; Citric acid,hydrous; Citric Acid,(S); Citric acid, hydrous; Citric acid (8CI); K-Lyte (Salt/Mix); 1i2s; 1o4l; 1rq2; 1y4a; 2bo4; 2c4v; 2fw6; 4to8; Citraclean (Salt/Mix); Citric acid-[13C6]; Citric Acid (Anhydrous); 10402-15-0; Spectrum3_001850; WLN: QV1XQVQ1VQ; beta-Hydroxytricarballylate; cid_311; K-Lyte/Cl (Salt/Mix); K-Lyte DS (Salt/Mix); Acidum citricum monohydrate; bmse000076; HOC(CH2COOH)2COOH; EC 201-069-1; NCIStruc1_000057; NCIStruc2_000099; NCIOpen2_004062; NCIOpen2_004502; Oprea1_502996; BSPBio_003240; Citric acid anhydrous (JAN); 4-03-00-01272 (Beilstein Handbook Reference); Citric Acid, anhydrous, USP; MLS001066346; citric acid (Fragrance Grade); Citric acid, anhydrous (USP); Anhydrous citric acid (JP17); GTPL2478; INS NO.330; Citric Acid (Industrial Grade); Citric acid, analytical standard; DTXSID3020332; BDBM14672; Citric acid, p.a., 99.5%; KBio3_002740; INS-330; 4o61; Citric acid 5% solution in water; Citric acid, Electrophoresis Grade; HMS1787N01; HMS2268B04; Pharmakon1600-01300013; ZINC895081; Citric acid 10% solution in water; HY-N1428; STR12052; 1,2,3-Tricarboxy-2-hydroxypropane; Tox21_113436; Tox21_202405; Tox21_300124; BBL002530; NSC759606; s5761; STK286098; AKOS000119911; Citric acid, LR, anhydrous, >=99%; 2-hydroxy-1,2,3-propanetricarboxylate; CS-6965; DB04272; MCULE-7981253226; NSC-759606; 3-Carboxy-3-hydroxypentane-1,5-dioate; Citric acid, >=99.5%, FCC, FG; Citric acid, ACS reagent, >=99.5%; Citric Acid, anhydrous powder, A.C.S.; 2-Hydroxy-1,3-propanetricarboxylic acid; NCGC00090954-01; NCGC00090954-02; NCGC00090954-04; NCGC00090954-05; NCGC00254055-01; NCGC00259954-01; BP-31028; Citric Acid, anhydrous granular, A.C.S.; NCI60_022579; SMR000471840; 2-hydroxy-1,2,3-propanetricarboxyic acid; Citric acid 50% solution in water (w/w); SBI-0206765.P001; Citric acid, SAJ first grade, >=99.5%; 2-Hydroxy-1,2,3-propane tricarboxylic acid; 2-Hydroxy-1,2,3-propanenetricarboxylic acid; B7297; C1949; Citric Acid, Aqueous Solution (Food Grade); Citric acid, Vetec(TM) reagent grade, 99%; E-330; FT-0623957; FT-0665073; FT-0728530; C00158; D00037; AE-562/40806920; Citric acid, BioUltra, anhydrous, >=99.5% (T); Q159683; J-520099; 1,2,3-Propanetricarboxylic acid, 2-hydroxy- (9CI); Z56754862; Citric acid (monohydrate): H2O = 1 g : 1 ml solution; Citric acid, certified reference material, TraceCERT(R); Citric acid, meets USP testing specifications, anhydrous; F2191-0222; 8F5D336A-442D-434A-9FB0-E400FF74E343; Citrate standard for IC, 1000 mg/L, analytical standard; 1,2,3-PROPANETRICARBOXYLIC ACID,2-HYDROXY  (CITRIC ACID); Citric acid, United States Pharmacopeia (USP) Reference Standard; Citric acid, anhydrous, cell culture tested, plant cell culture tested; Citric acid, anhydrous, European Pharmacopoeia (EP) Reference Standard; Citric acid, anhydrous, free-flowing, Redi-Dri(TM), ACS reagent, >=99.5%; Citric acid, Anhydrous, Pharmaceutical Secondary Standard; Certified Reference Material; Citric acid, meets analytical specification of Ph. Eur., BP, USP, E330, anhydrous, 99.5-100.5% (based on anhydrous substance)	IC50 = 488000 nM	.	10.1039/C4MD00256C	.	.	.
REG00003	XENOBIOTIC00039	Dabigatran	216210	Dabigatran; 211914-51-1; BIBR 953; BIBR-953; 3-[[2-[(4-carbamimidoylanilino)methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoic acid; CHEBI:70752; BIBR 953 (Dabigatran, Pradaxa); UNII-I0VM4M70GC; I0VM4M70GC; BIBR 953 ZW; CHEMBL48361; 3-[[2-[[(4-CARBAMIMIDOYLPHENYL)AMINO]METHYL]-1-METHYL-BENZOIMIDAZOLE-5-CARBONYL]-PYRIDIN-2-YL-AMINO]PROPANOIC ACID; N-[(2-{[(4-Carbamimidoylphenyl)amino]methyl}-1-Methyl-1h-Benzimidazol-5-Yl)carbonyl]-N-Pyridin-2-Yl-Beta-Alanine; 3-(2-(((4-carbamimidoylphenyl)amino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoic acid; C25H25N7O3; 3-[1-(2-{[(4-carbamimidoylphenyl)amino]methyl}-1-methyl-1H-1,3-benzodiazol-5-yl)-N-(pyridin-2-yl)formamido]propanoic acid; BIBR953; beta-Alanine, N-((2-(((4-(aminoiminomethyl)phenyl)amino)methyl)-1-methyl-1H-benzimidazol-5-yl)carbonyl)-N-2-pyridinyl-; BETA-ALANINE, N-[[2-[[[4-(AMINOIMINOMETHYL)PHENYL]AMINO]METHYL]-1-METHYL-1H-BENZIMIDAZOL-5-YL]CARBONYL]-N-2-PYRIDINYL-; Pradaxa (dabigatran); Dabigatran-[13C6]; Dabigatran-D3 solution; Dabigatran (USAN/INN); BIBR 953(Dabigatran); Epitope ID:186729; Dabigatran (BIBR-953); SCHEMBL3573; BIBR 953ZW; BIBR-953ZW; BIBR-953-ZW; Dabigatran [USAN:INN:BAN]; GTPL6380; BIBR 953,Dabigatran, Pradaxa; HSDB 8062; AOB5262; DTXSID50175419; BCP06664; ZINC1910616; BDBM50112086; BIBR 953 - Dabigatran - Pradaxa; MFCD09837830; s2196; STL450902; AKOS005266720; AM81238; CS-1399; DB14726; PB38204; SB20292; NCGC00346575-01; NCGC00346575-06; (non-labelled)Dabigatran-d4 Hydrochloride; AC-25299; AS-11488; HY-10163; BIBR 953 (Dabigatran etexilate, Pradaxa); FT-0648482; FT-0665441; 2,6-Bis[(R)-4-phenyloxazolin-2-yl]pyridine; C21556; D09707; AB01274802-01; AB01274802_02; A815190; Q419345; Q-102529; 1-Methyl-2-[(4-amidinophenyl)aminomethyl]benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-hydroxycarbonylethyl)amide; 1-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-hydroxycarbonylethyl)-amide; 1-Methyl-2-[N-(4-amidinophenyl)aminomethyl]benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-hydroxycarbonylethyl)amide; 3-(((2-(((4-Carbamimidoylphenyl)amino)methyl)-1-methyl-1H-benzimidazol-5-yl)carbonyl)(pyridin-2-yl)amino)propanoic acid; 3-({2-[(4-Carbamimidoyl-phenylamino)-methyl]-1-methyl-1H-benzoimidazole-5-carbonyl}-pyridin-2-yl-amino)-propionic acid; 3-[[[2-[(4-carbamimidoylanilino)methyl]-1-methyl-5-benzimidazolyl]-oxomethyl]-(2-pyridinyl)amino]propanoic acid; 3-[[2-[[(4-carbamimidoylphenyl)amino]methyl]-1-methyl-benzimidazol-5-yl]carbonyl-pyridin-2-yl-amino]propanoic acid; 3-[[2-[[(4-carbamimidoylphenyl)amino]methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoic acid; b-Alanine,N-[[2-[[[4-(aminoiminomethyl)phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-2-pyridinyl-; N-((2-((p-Amidinoanilino)methyl)-1-methyl-5-benzimidazolyl)carbonyl)-N-2-pyridyl-beta-alanine	IC50=60000 nM	.	22494098	.	.	.
REG00003	XENOBIOTIC00040	3-[[2-[[4-[N'-[4-[[(3S)-4-[3-[2-[2-[3-[5-[(3aS,4S,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]propoxy]ethoxy]ethoxy]propylamino]-4-oxo-3-[[4-[3-(trifluoromethyl)diazirin-3-yl]benzoyl]amino]butanoyl]amino]butyl]carbamimidoyl]anilino]methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoic acid	57415280	CHEMBL2216801	IC50=800 nM	.	22494098	.	.	.
REG00006	XENOBIOTIC00041	N~2~-hexyl-6,7-dimethoxy-N~4~-(1-methylpiperidin-4-yl)quinazoline-2,4-diamine	137348638	CHEMBL4086403; SCHEMBL23260478; MS012; BDBM50501525; MS 012; MS-012; N~2~-hexyl-6,7-dimethoxy-N~4~-(1-methylpiperidin-4-yl)quinazoline-2,4-diamine; 2089617-83-2	IC50=7&plusmn;2 nM	.	28135087	.	.	.
REG00006	XENOBIOTIC00042	6,7-Dimethoxy-N-(1-Methylpiperidin-4-Yl)-2-(Morpholin-4-Yl)quinazolin-4-Amine	44605026	CHEMBL571717; 6,7-Dimethoxy-N-(1-Methylpiperidin-4-Yl)-2-(Morpholin-4-Yl)quinazolin-4-Amine; 7L6; SCHEMBL15280520; BDBM50300032; NCGC00185861-01; 6,7-dimethoxy-N-(1-methylpiperidin-4-yl)-2-morpholinoquinazolin-4-amine	IC50=13 &plusmn; 4 nM	.	28135087	.	.	.
REG00007	XENOBIOTIC00041	N~2~-hexyl-6,7-dimethoxy-N~4~-(1-methylpiperidin-4-yl)quinazoline-2,4-diamine	137348638	CHEMBL4086403; SCHEMBL23260478; MS012; BDBM50501525; MS 012; MS-012; N~2~-hexyl-6,7-dimethoxy-N~4~-(1-methylpiperidin-4-yl)quinazoline-2,4-diamine; 2089617-83-2	IC50=7&plusmn;2 nM	.	28135087	.	.	.
REG00007	XENOBIOTIC00042	6,7-Dimethoxy-N-(1-Methylpiperidin-4-Yl)-2-(Morpholin-4-Yl)quinazolin-4-Amine	44605026	CHEMBL571717; 6,7-Dimethoxy-N-(1-Methylpiperidin-4-Yl)-2-(Morpholin-4-Yl)quinazolin-4-Amine; 7L6; SCHEMBL15280520; BDBM50300032; NCGC00185861-01; 6,7-dimethoxy-N-(1-methylpiperidin-4-yl)-2-morpholinoquinazolin-4-amine	IC50=13 &plusmn; 4 nM	.	28135087	.	.	.
REG00009	XENOBIOTIC00043	4-(dimethylamino)-N-[3-[[2-(4-oxochromen-7-yl)oxyacetyl]amino]phenyl]benzamide	155513187	CHEMBL4438748; BDBM50519662	IC50=3141 nM	.	31693351	.	.	.
REG00004	XENOBIOTIC00044	TL13-68	145963683	TL13-68; CHEMBL4129274; BDBM50269622; HY-136849; CS-0134015	IC50=33 nM	.	28038940	.	.	.
REG00008	XENOBIOTIC00044	TL13-68	145963683	TL13-68; CHEMBL4129274; BDBM50269622; HY-136849; CS-0134015	IC50=33 nM	.	28038940	.	.	.
REG00011	XENOBIOTIC00046	Rentinolol	11228149	CHEMBL2170196; Rentinolol; Wrenchnolol; SCHEMBL14003415; BDBM50396057	IC50=6900 nM	.	33622787	.	.	.
REG00012	XENOBIOTIC00047	PMID34895045-Compound-7773	.	.	IC50 = 30.45 uM	.	34895045	.	.	.
REG00013	XENOBIOTIC00048	Lapatinib	208908	Lapatinib; 231277-92-2; Lapatinib Ditosylate; Tykerb; GW572016; Lapatinib base; GW 572016; Tyverb; 388082-78-8; Lapatinib free base; UNII-0VUA21238F; Lapatinib (free base); 231277-92-2 (free base); GSK572016; MFCD09264194; FMM; N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)furan-2-yl)quinazolin-4-amine; N-{3-CHLORO-4-[(3-FLUOROBENZYL)OXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]-4-QUINAZOLINAMINE; N-{3-chloro-4-[(3-fluorophenyl)methoxy]phenyl}-6-(5-{[(2-methanesulfonylethyl)amino]methyl}furan-2-yl)quinazolin-4-amine; CHEMBL554; N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine; CHEBI:49603; 0VUA21238F; NSC745750; GW-572016; NCGC00167507-01; C29H26ClFN4O4S; DSSTox_CID_26675; DSSTox_RID_81812; DSSTox_GSID_46675; 1210608-87-9; Lapatinib (INN); 4-Quinazolinamine, N-(3-chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-; 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-; N-(3-chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine; N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-(5-((2-(methylsulfonyl)ethylamino)methyl)furan-2-yl)quinazolin-4-amine; n-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-4-quinazolinamine; N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)furan-2-yl]quinazolin-4-amine; GSK 572016; CAS-231277-92-2; GW-2016; Lapatinib [INN:BAN]; GW 282974X; HSDB 8209; 1xkk; N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; Lapatinib, Free base; Lapatinib 13C-D7; nchembio866-comp20; Kinome_3684; Kinome_3685; Lapatinib base- Bio-X; SCHEMBL8100; Lapatinib (GW572016); BDBM5445; cid_208908; GTPL5692; QCR-63; DTXSID7046675; AOB5254; EX-A402; SYN1052; BCPP000188; BCPP000189; HMS2089H10; HMS3244N06; HMS3244N10; HMS3244N14; HMS3744K11; Tykerb (TN) (Glaxo Smith Kline); BCP01874; ZINC1550477; Tox21_112505; NSC800780; AKOS005145766; Tox21_112505_1; AC-1314; BCP9000837; BCP9000838; CCG-270133; CM14421; DB01259; GSK-572016; GW-572016X; NSC-745750; NSC-800780; SB16918; NCGC00167507-02; NCGC00167507-03; NCGC00167507-04; NCGC00167507-09; 913989-15-8; AS-14065; BC164610; HY-50898; N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-((2-methylsulfonylethylamino)methyl)-2-furyl)quinazolin-4-amine; N-(3-Chloro-4-{[(3-fluorophenyl)methyl]oxy}phenyl)-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furanyl]-4-quinazolinamine; Q570; AM20090641; FT-0659650; SW199101-5; A25184; D08108; J90020; AB01273965-01; AB01273965-02; AB01273965-03; AB01273965_04; AB01273965_05; 277L922; Q420323; Q-101353; SR-05000001472-1; BRD-K19687926-001-01-7; BRD-K19687926-379-02-5; GW572016;GW-572016;GW 572016; 1092929-10-6; GW-2016;N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)furan-2-yl)quinazolin-4-amine;4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[(2-methanesulfonylethyl)amino]methyl]furan-2-yl]quinazoline; N-[3-chloro-4-(3-fluorobenzyloxy)phenyl]-6-[5-({[2-(methanesulfonyl)ethyl]amino}methyl)furan-2-yl]quinazolin-4-amine; N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]-2-furyl] quinazolin-4-amine; N-{3-chloro-4-[(3-fluoro-benzyl)oxy]phenyl}-6-[5-({2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methane sulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; N-{3-Chloro-4[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methane sulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; N3-Chloro-4-(3-fluorophenyl)methoxyphenyl-6-5-(2-methylsulfonylethylamino)methyl-2-furylquinazolin-4-amine	IC50 = 9.95uM (TPC1SR cell)	.	34896211	.	.	.
REG00027	XENOBIOTIC00059	Vemurafenib	42611257	Vemurafenib; 918504-65-1; PLX4032; Zelboraf; 1029872-54-5; PLX-4032; N-(3-(5-(4-Chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl)propane-1-sulfonamide; RG7204; PLX 4032; RG 7204; Vemurafenib (PLX4032, RG7204); Vemurafenib (PLX4032); RO5185426; RO 5185426; N-(3-{[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]carbonyl}-2,4-difluorophenyl)propane-1-sulfonamide; UNII-207SMY3FQT; RG-7204; 207SMY3FQT; CHEBI:63637; MFCD18074504; NSC761431; Vemurafenib;PLX-4032; RO-5185426; C23H18ClF2N3O3S; 1-PROPANESULFONAMIDE, N-[3-[[5-(4-CHLOROPHENYL)-1H-PYRROLO[2,3-B]PYRIDIN-3-YL]CARBONYL]-2,4-DIFLUOROPHENYL]-; N-(3-((5-(4-Chlorophenyl)-1H-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4- difluorophenyl)propane-1-sulfonamide; N-[3-[[5-(4-Chlorophenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]carbonyl]-2,4-difluorophenyl]-1-PropanesulfonaMide; N-[3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluorophenyl]propane-1-sulfonamide; N-{3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluorophenyl}propane-1-sulfonamide; Zelboraf (TN); 1-Propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1H-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-; n-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-1-propanesulfonamide; Vemurafenib [USAN:INN]; vemurafenibum; Ro 51-85426; HSDB 8143; N-(3-{(5-(4-chlorophenyl)-1H-pyrrolo(2,3-b)pyridin-3-yl)carbonyl}-2,4- difluorophenyl)propane-1-sulfonamide; 3og7; Vemurafenib; PLX4032; PLX4032 - Vemurafenib; SCHEMBL298931; Vemurafenib (JAN/USAN/INN); GTPL5893; QCR-44; CHEMBL1229517; DTXSID50238710; EX-A053; SYN1161; HMS3265M03; HMS3265M04; HMS3265N03; HMS3265N04; HMS3654P09; HMS3748G15; AOB87705; BCP25783; EX-A1335; BDBM50396483; NSC800964; s1267; ZINC52509366; AKOS007930804; ACN-030372; AM81259; CCG-264883; CS-0216; DB08881; MCULE-7244406627; ME-0096; NSC-761431; NSC-800964; PB11741; NCGC00250399-01; NCGC00250399-05; NCGC00250399-08; Vemurafenib, RG7204, RO5185426; 1-Propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1H-pyrrolo(2,3-b)pyridin-3- yl)carbonyl)-2,4-difluorophenyl)-; AC-25010; HY-12057; N-[3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl]propane-1-sulfonamide; SY067868; FT-0660388; FT-0675792; FT-0689782; SW218095-2; Y0473; RO-51-85426; A25476; A25742; D09996; R-7204; AB01273970-01; AB01273970_03; Q423111; SR-01000941568; carbonyl]-2,4-difluorophenyl}propane-1-sulfonamide; J-522975; J-690009; SR-01000941568-1; BRD-K56343971-001-02-3; BRD-K56343971-001-05-6; PLX4032,Vemurafenib, RG7204, RO5185426, Zelboraf; N-{3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-; [(2S,5R)-2,5-Dimethyl-4-[(tetrahydro-2H-pyran-4-yl)methyl]-1-piperazinyl][3-[(5-fluoro-2-methyl-4-pyrimidinyl)amino]-4,6-dihydro-6,6 -dimethylpyrrolo[3,4-c]pyrazol-5(1H)-yl]methanone; 1415041-85-8; N-(3-(5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl)-propane-1-sulfonamide; propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide	IC50=5000 nM	.	29156680	.	.	.
REG00010	XENOBIOTIC00045	Fenson	6636	Fenson; 80-38-6; Fensone; Murvesco; Aracid; PCBS; Phenizon; 4-CHLOROPHENYL BENZENESULFONATE; Fenizon; CPBS; PCPBS; Ovicide Seppic; Benzenesulfonic acid, 4-chlorophenyl ester; (4-chlorophenyl) benzenesulfonate; p-Chlorophenyl benzenesulfonate; p-Chlorophenyl benzenesulphonate; 4-Chlorophenyl benzenesulphonate; Benzenesulfonic acid, p-chlorophenyl ester; ENT 4,585; GC-928; (4-Chlor-phenyl)-benzolsulfonat; UNII-DFC2HB4I0K; (4-Cloro-fenil)-benzol-solfonato; (4-Chloor-fenyl)-benzeen-sulfonaat; NSC 406662; PCPB; p-Chlorofenylester kyseliny benzensulfonove; Benzenesulfonate de 4-chlorophenyle; DFC2HB4I0K; PCI; CHEBI:82160; Fenizon [French]; Caswell No. 207; Fenson [BSI:ISO]; HSDB 2054; para-Chlorophenyl benzenesulfonate; Polychlorinated biphenyls; EINECS 201-274-6; EPA Pesticide Chemical Code 020101; BRN 2696927; (4-Chlor-phenyl)-benzolsulfonat [German]; AI3-04585; (4-Chloor-fenyl)-benzeen-sulfonaat [Dutch]; (4-Cloro-fenil)-benzol-solfonato [Italian]; Benzenesulfonate de 4-chlorophenyle [French]; p-Chlorofenylester kyseliny benzenesulfonove [Czech]; p-Chlorofenylester kyseliny benzensulfonove [Czech]; p-Chlorofenylester kyseliny benzenesulfonove; WLN: WSR&OR DG; DSSTox_CID_21973; DSSTox_RID_79891; DSSTox_GSID_41973; SCHEMBL165491; CHEMBL1495617; DTXSID6041973; ZINC1599346; Tox21_301324; NSC406662; AKOS001592601; MCULE-8023140500; NSC-406662; CAS-80-38-6; Aracidbenzenesulfonate de 4-chlorophenyle; Benzenesulfonic acid,4-chlorophenyl ester; NCGC00166192-01; NCGC00255899-01; Fenson, PESTANAL(R), analytical standard; C19030; Q22807557	.	PCIF1 and PUS10, respectively, in HFD + PCB 126- + Aroclor 1260-exposed mouse liver.	34548932	.	.	.
REG00014	XENOBIOTIC00049	PMID29703820-Compound-JQ1	.	.	.	The bromodomain and extraterminal domain inhibitor (BETi) JQ1 decreased IGF2BP3 expression.	29703820	.	.	.
REG00017	XENOBIOTIC00050	Butyrate	104775	butyrate; butanoate; N-Butyrate; n-butanoate; Butanoic acid, ion(1-); propylformate; 461-55-2; butanate; 1-butanoate; propanecarboxylate; 1-butyrate; 1-propanecarboxylate; CHEMBL62381; NCGC00167555-01; ethyl,acetate; Sodium; butyrate; C11H23NOS; DTXSID8040432; CHEBI:17968; CH3-[CH2]2-COO(-); BDBM50079401; c0035; M135; AB01566831_01; Q55582441	.	In cell model induced by sodium butyrate and cell density, while METTL3, METTL16 and WTAP were decreased during the differentiation of cells.	33571906	.	.	.
REG00019	XENOBIOTIC00051	Geniposide	107848	Geniposide; 24512-63-8; Jasminoidin; UNII-145295QLXY; CHEBI:5299; 145295QLXY; 169799-41-1; methyl (1S,4aS,7aS)-7-(hydroxymethyl)-1-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,4a,5,7a-tetrahydrocyclopenta[c]pyran-4-carboxylate; Cyclopenta[c]pyran-4-carboxylic acid, 1-(beta-D-glucopyranosyloxy)-1,4a,5,7a-tetrahydro-7-(hydroxymethyl)-, methyl ester, (1S,4aS,7aS)-; methyl (1S,4aS,7aR)-7-(hydroxymethyl)-1-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-1,4a,5,7a-tetrahydrocyclopenta[c]pyran-4-carboxylate; methyl (1S,4aS,7aS)-7-(hydroxymethyl)-1-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-1,4a,5,7a-tetrahydrocyclopenta[c]pyran-4-carboxylate; (1S,4aS,7aS)-Methyl 7-(hydroxymethyl)-1-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-1,4a,5,7a-tetrahydrocyclopenta[c]pyran-4-carboxylate; Cyclopenta(c)pyran-4-carboxylic acid, 1-(beta-D-glucopyranosyloxy)-1,4a,5,7a-tetrahydro-7-(hydroxymethyl)-, methyl ester, (1S,4aS,7aS)-; Genipin 1-glucoside; CHEMBL462894; Geniposide, >=98% (HPLC); AOB5625; HMS3884F17; ZINC3882101; BDBM50478840; MFCD16036219; s2411; AKOS025311228; CCG-268498; MCULE-3871054229; NCGC00346662-04; NCGC00346662-06; 27745-20-6; N1360; C09781; AB01558902_03; BRD-K57275767-001-03-2; Q27106709; Cyclopenta(c)pyran-4-carboxylic acid, 1-(beta-D-glucopyranosyloxy)-1,4a,5,7a-tetrahydro-7-(hydroxymethyl)-, methyl ester, (1S-(1alpha,4aalpha,7aalpha))-	.	Gardenia jasminoides extracts (GJE)  attenuated expression of cytokines (IL-1Beta, IL-6 and TNF-Alpha), NFKB activating protein (NKAP) and TLR4 in ARPE-19 cells.	34007309	.	.	.
REG00019	XENOBIOTIC00052	Crocin	5281233	Crocin; Gardenia Yellow; alpha-Crocin; 42553-65-1; Crocin I; Crocine; 94238-00-3; Crocin 1; Saffron; crocin-1; UNII-877GWI46C2; crocetin di-gentiobiose ester; CHEMBL446785; bis[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl] (2E,4E,6E,8E,10E,12E,14E)-2,6,11,15-tetramethylhexadeca-2,4,6,8,10,12,14-heptaenedioate; CHEBI:79068; Crocetin digentiobiose ester; 877GWI46C2; 11012-59-2; Crocetin bis(gentiobiosyl) ester; NCGC00160471-01; all-trans-Crocetin di-beta-D-gentiobiosyl ester; Crocin A; CCRIS 678; CCRIS 7705; crocetin digentiobiosyl ester; EINECS 255-881-6; BRN 6473367; .alpha.-crocin; Crocin-I; HSDB 8211; Natural red 1; EINECS 254-465-1; Natural yellow 19; crocetin digentiobioside; trans-Crocetin di(beta-D-gentiobiosyl) ester; DSSTox_CID_1457; DSSTox_RID_81403; DSSTox_GSID_46172; SCHEMBL1463936; DTXSID7046172; bis(beta-D-gentiobiosyl) crocetin; HMS3887O07; Crocetin Di(Beta-Gentiobiosyl)Ester; HY-N0697; crocetin di-beta-D-gentiobiose ester; Tox21_111837; BDBM50260195; s9511; AKOS015896765; ZINC245224178; DB11874; Bis(6-O-beta-D-glucopyranosyl-beta-D-glucopyranosyl) 8,8'-diapo-psi,psi-carotenedioate; NCGC00160471-02; 8,8'-Diapo-psi,psi-carotenedioic acid, bis(6-O-beta-D-glucopyranosyl-beta-D-glucopyranosyl) ester; beta-D-Glucopyranose, 6-O-beta-D-glucopyranosyl-, 1,1'-((2E,4E,6E,8E,10E,12E,14E)-2,6,11,15-tetramethyl-2,4,6,8,10,12,14-hexadecaheptaenedioate); CAS-42553-65-1; C.I. 75100; CS-0009714; N1653; N1661; N1889; trans-crocetin bis(beta-D-gentiobiosyl) ester; C08589; A872860; Q424767; UNII-F32BA2H92Z component SEBIKDIMAPSUBY-RTJKDTQDSA-N; (2E,4E,6E,8E,10E,12E,14E)-Bis((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-((((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)methyl)tetrahydro-2H-pyran-2-yl) 2,6,11,15-tetramethylhexadeca-2,4,6,8,10,12,14-heptaenedioate; bis(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-({[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl (2E,4E,6E,8E,10E,12E,14E)-2,6,11,15-tetramethylhexadeca-2,4,6,8,10,12,14-heptaenedioate; bis[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-({[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl]oxy}methyl)tetrahydro-2H-pyran-2-yl] (2E,4E,6E,8E,10E,12E,14E)-2,6,11,15-tetramethylhexadeca-2,4,6,8,10,12,14-heptaenedioate	.	Gardenia jasminoides extracts (GJE)  attenuated expression of cytokines (IL-1Beta, IL-6 and TNF-Alpha), NFKB activating protein (NKAP) and TLR4 in ARPE-19 cells.	34007309	.	.	.
REG00020	XENOBIOTIC00053	Tretinoin	444795	Retinoic acid; tretinoin; 302-79-4; all-trans-Retinoic acid; Vitamin A acid; trans-Retinoic acid; ATRA; Airol; Retin-A; Vesanoid; Aberel; Eudyna; Renova; All-trans Retinoic Acid; all-trans-Vitamin A acid; Dermairol; Aknoten; Aknefug; Cordes vas; Epi-aberel; TRETINON; Tretin M; Atralin; all-trans-Vitamin A1 acid; all-trans-Tretinoin; Retionic acid; All Trans Retinoic Acid; Vitamin A1 acid, all-trans-; Retin-A Micro; Retin A; beta-Retinoic acid; all-(E)-Retinoic acid; Vitamin A acid, all-trans-; Retinoate; (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid; Retinoic acid, all-trans-; Alltrans-retinoic acid; Retacnyl; Vesnaroid; NSC-122758; Ro 1-5488; Tretinoin, all-trans-; all trans-Retinoic acid; Stieva-A; Tretinoine; Solage; all-trans-beta-Retinoic acid; Effederm; .beta.-Retinoic acid; Tretinoin/All-Trans Retinoic Acid; Aberela [Norway]; Avitoin [Norway]; Effederm [France]; UNII-5688UTC01R; A-Acido (Argentina); 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid; (all-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid; MLS000028588; b-Retinoic acid; RETINOIC ACID, ALL TRANS; Tretinoine [INN-French]; Tretinoinum [INN-Latin]; AT-RA; Tretinoina [INN-Spanish]; Tretinoino [INN-Spanish]; CHEMBL38; (2E,4E,6E,8E)-3,7-Dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenoic acid; 2,4,6,8-Nonatetraenoic acid, 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (all-E)-; MFCD00001551; NSC122758; Atragen; Retinova; SMR000058245; (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid; CHEBI:15367; 15-Apo-beta-caroten-15-oic acid; 5688UTC01R; Tretinoin (TN); beta-Ra; Acnavit [Denmark]; AGN 100335; REA; 9-cis-RA; Retin A (TN); NCGC00017280-10; Tretinoinum; Aberela; Acnavit; Avitoin; Betarretin; Tretinoina; Tretinoino; A-Vitaminsyre; all-trans-b-Retinoic acid; DSSTox_CID_1239; Cordes VAS [Germany]; A-Vitaminsyre [Denmark]; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexene-1-yl)-2,4,6,8-nonatetraenoic acid (ECL); DSSTox_RID_76031; DSSTox_GSID_21239; trans-Retinoate; beta-Retinoate; tretinoine (French) (EINECS); cis-Retinoic acid; Acide retinoique (French) (DSL); Refissa; Nexret; Vitamin a acid, trans-; Retisol-A; Acid A Vit (Belgium, Netherlands); 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)nona-2,4,6,8-tetraenoic acid; 3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2E,4E,6E,8E-tetraenoic acid; (11Z)-retinoic acid; (2E,4E,6E,8E)-3,7-Dimethyl-9-(2,6,6-trimethyl-cyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid; [3H]Retinoic acid; Renova (TN); CCRIS 3294; Avita (TN); HSDB 2169; SR-01000000239; EINECS 206-129-0; NSC 122758; BRN 2057223; Tretinoin (JAN/USP/INN); Kerlocal; Retinoic acid, cis-9,trans-13-; TNP00194; Oristar rna; BML2-E05; DTXSID7021239; 1cbr; [3H]tretinoin; [All-E]-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid; Tretinoin [USAN:USP:INN:BAN]; CAS-302-79-4; Prestwick_424; all-(E)-Retinoate; Tretinoine (French); Retinoic acid, cis-; (5E)-Retinoic acid; [3H]Vitamin A acid; 1n4h; CPD000058245; Retinoic acid all trans; 6-s-trans-retinoic acid; Vitamin-A-sA currencyure; Opera_ID_1055; Prestwick2_000257; Prestwick3_000257; Spectrum5_001746; Spectrum5_001933; acide retinoique (French); Vesanoid (TN) (Roche); Tretinoin - Retinoic Acid; bmse000562; UPCMLD-DP097; R 2625; Renova (0.02% cream); SCHEMBL3145; (9Z,13Z)-Retinoic acid; 3,7-Dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-all-trans-tetraenoic acid; Altreno (0.05% lotion); BIDD:PXR0081; Lopac0_001061; Avita (0.025% gel); BSPBio_000074; BSPBio_001500; MLS001076515; MLS002207234; MLS002222211; MLS002548861; MLS006010222; BIDD:GT0483; SPECTRUM1502016; 9-cis-retinoic acid (9cRA); [3H]RA; BPBio1_000082; cid_444795; GTPL2644; .beta.-all-trans-Retinoic acid; all-trans-retinoic acid (ATRA); SCHEMBL19091395; BDBM31883; HMS502N05; QCR-120; BCPP000036; BDBM323588; HMS1361K22; HMS1568D16; HMS1791K22; HMS1921D14; HMS1989K22; HMS2089D20; HMS2092N11; HMS2095D16; HMS2236N03; HMS3259E11; HMS3263E04; HMS3402K22; HMS3411B09; HMS3675B09; HMS3712D16; Pharmakon1600-01502016; Retinoic acid, all-trans- (8CI); 124510-04-9; 2,4,6,8-Nonatetraenoic acid, 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (2E,4E,6Z,8E)-; 68070-35-9; ACT00012; BCP01405; US10188615, at-RA; Tox21_110812; Tox21_202330; Tox21_300305; Tox21_501061; All-trans Retinoic Acid (Tretinoin); CCG-39912; LMPR01090019; NSC759631; s1653; ZINC12358651; AKOS000280845; Tox21_110812_1; AC-6824; CS-1269; DB00755; GS-3578; LP01061; NC00481; NSC-759631; SDCCGSBI-0051031.P004; IDI1_000903; IDI1_033970; NCGC00017280-05; NCGC00017280-06; NCGC00017280-07; NCGC00017280-08; NCGC00017280-09; NCGC00017280-12; NCGC00017280-15; NCGC00017280-16; NCGC00017280-17; NCGC00017280-18; NCGC00017280-19; NCGC00017280-20; NCGC00017280-23; NCGC00017280-38; NCGC00021808-04; NCGC00021808-05; NCGC00021808-06; NCGC00021808-07; NCGC00021808-09; NCGC00021808-11; NCGC00021808-14; NCGC00021808-15; NCGC00254179-01; NCGC00259879-01; NCGC00261746-01; trans-Retinoic acid; ; ; Retinoid analogues; BP-20401; BR164493; HY-14649; Retinoic acid, >=98% (HPLC), powder; SBI-0051031.P003; EU-0101061; R0064; SW203749-4; 02T794; C00777; D00094; J10054; Q29417; AB00052318-15; AB00052318-16; AB00052318-17; AB00052318_18; AB00052318_19; A899883; L000833; Q-200610; SR-01000000239-3; SR-01000000239-4; SR-01000000239-6; SR-01000000239-7; BRD-K06926592-001-01-7; BRD-K71879491-001-15-0; BRD-K71879491-001-22-6; SR-01000000239-12; SR-01000000239-13; SR-01000000239-14; SR-01000000239-15; WLN: L6UTJ A1 B1U1Y1&U2U1Y1&U1VQ C1 C1; Tretinoin, European Pharmacopoeia (EP) Reference Standard; WLN: L6UTJ A1 B1U1Y1 & U2U1Y1 & U1VQ C1 C1; Tretinoin, United States Pharmacopeia (USP) Reference Standard; 3,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid; Tretinoin, Pharmaceutical Secondary Standard; Certified Reference Material; (2E,4E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)-2,4,6,8-nonatetraenoic acid; (4E,6E,8E)-9-(2,6,6-Trimethyl-1-cyclohexenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; (all-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoate; 2,4,6,8-Nonatetranoic acid, 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-; 2,6,8-Nonatetranoic acid, 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoate; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2E,4E,6E,8E,-nonatetraenoic acid; all-trans-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic Acid; 2,4, 6,8-Nonatetranoic acid, 3,7-dimethyl-9-(2,6, 6-trimethyl-1-cyclohexen-1-yl)-, (2E, 4E, 6E, 8E)-; 2,4,6,8-Nonatetraenoic acid, 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)--, (all trans)-; 2,4,6,8-Nonatetranoic acid, 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (all trans)-; 2,6,8-Nonatetraenoic acid, 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (all-E)-; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid-, (all trans)-; 97950-17-9	.	To obtain and identify the differential proteome of apoptosis induced by realgar (tetra-arsenic tetra-sulfide, As(4)S(4)) in retinoid acid (RA) resistant human acute promyelocytic leukemia (APL) cell line NB4-R1 cells.up-regulated RBM15 after exposed for 48 h.	21223730	.	.	.
REG00022	XENOBIOTIC00054	Beta-Elemene	6918391	BETA-ELEMENE; 515-13-9; beta-Elemen; (-)-beta-Elemene; Levo-beta-elemene; b-elemene; Levo-b-elemene; UNII-2QG8CX6LXD; (1S,2S,4R)-1-methyl-2,4-di(prop-1-en-2-yl)-1-vinylcyclohexane; 2,4-Diisopropenyl-1-methyl-1-vinylcyclohexane; (-)-b-Elemene; CHEBI:62855; 2QG8CX6LXD; (1S,2S,4R)-2,4-diisopropenyl-1-methyl-1-vinylcyclohexane; (1S,2S,4R)-(-)-1-methyl-1-vinyl-2,4-diisopropenylcyclohexane; (1S,2S,4R)-1-ethenyl-1-methyl-2,4-bis(prop-1-en-2-yl)cyclohexane; Cyclohexane, 1-ethenyl-1-methyl-2,4-bis(1-methylethenyl)-, (1S,2S,4R)-; 33880-83-0; (1S,2S,4R)-1-ethenyl-1-methyl-2,4-di(prop-1-en-2-yl)cyclohexane; beta-Elemene, (-)-; b-Elemen; E- .beta.-Elemene; Epitope ID:153551; Levo-b-elemene(-)-b-Elemene; CHEMBL448502; DTXSID60881211; SDP-111; 8064AH; s6957; ZINC14096289; AKOS028108977; (-)-beta-Elemene, analytical standard; Cyclohexane, 1-ethenyl-1-methyl-2,4-bis(1-methylethenyl)-, (1S-(1-alpha,2-beta,4-beta))-; Cyclohexane, 1-ethenyl-1-methyl-2,4-bis(1-methylethenyl)-, [1S-(1alpha,2beta,4beta)]-; AS-82909; HY-107324; CS-0028143; C17094; E79113; 880E830; Q27132237; 1-ethenyl-1-methyl-2,4-bis(1-methylethenyl)-cyclohexane; Cyclohexane, 2,4-diisopropenyl-1-methyl-1-vinyl-, (1S,2S,4R)-	.	Indicated that Beta-elemene administration led to the augment of YTHDC1 level was upregulated	35069732	.	.	.
REG00023	XENOBIOTIC00055	Trichostatin A	444732	trichostatin A; 58880-19-6; Trichostatin; TSA; Trichostatin A (TSA); (2E,4E,6R)-7-[4-(Dimethylamino)phenyl]-N-hydroxy-4,6-dimethyl-7-oxohepta-2,4-dienamide; UNII-3X2S926L3Z; Antibiotic A-300; CHEBI:46024; C17H22N2O3; GNF-PF-1011; 3X2S926L3Z; 58880-19-6 (R-isomer); 2,4-Heptadienamide, 7-(4-(dimethylamino)phenyl)-N-hydroxy-4,6-dimethyl-7-oxo-; 7-(4-(Dimethylamino)phenyl)-N-hydroxy-4,6-dimethyl-7-oxo-2,4-heptadienamide; MFCD03848392; (R,2E,4E)-7-(4-(dimethylamino)phenyl)-N-hydroxy-4,6-dimethyl-7-oxohepta-2,4-dienamide; A-300-I; (2E,4E,6R)-7-(4-(dimethylamino)phenyl)-N-hydroxy-4,6-dimethyl-7-oxo-2,4-heptadienamide; [R-(E,E)]-7-[4-(Dimethylamino)phenyl]-N-hydroxy-4,6-dimethyl-7-oxo-2,4-heptadienamide; 2,4-Heptadienamide, 7-[4-(dimethylamino)phenyl]-N-hydroxy-4,6-dimethyl-7-oxo-, (2E,4E,6R)-; Trichostatin-A; Tricostatin A; 7-[4-(DIMETHYLAMINO)PHENYL]-N-HYDROXY-4,6-DIMETHYL-7-OXO-2,4-HEPTADIENAMIDE; 2,4-Heptadienamide, 7-(4-(dimethylamino)phenyl)-N-hydroxy-4,6-dimethyl-7-oxo-, (2E,4E,6R)-; TSN; Trichostatina; trichostatine a; Trichlostatin A; Trichostatin(s); (2E,4E,6R)-7-(4-dimethylaminophenyl)-4,6-dimethyl-7-oxo-hepta-2,4-dienehydroxamic acid; (2E,4E,6R)-7-(4-Dimethylaminophenyl)-N-hydroxy-4,6-dimethyl-7-oxo-hepta-2,4-dienamide; Trichostatin A,TSA; (R)-Trichostatin A; NCGC_TSA; 1c3r; 3f0r; Trichostatin-A - TSA; SCHEMBL19886; MLS006011095; SGCTO-002; SCHEMBL675951; GTPL7005; DTXSID6037063; CHEBI:93196; BCPP000035; HMS1362L09; HMS1792L09; HMS1990L09; HMS3403L09; HMS3649O20; BCP01776; EX-A1665; Trichostatin A, Ready Made Solution; BDBM50005711; LMPK01000055; s1045; Trichostatin A from Streptomyces sp.; AKOS015899840; ZINC100014731; CCG-208142; CCG-208681; CS-0499; DB04297; NSC 311042; NCGC00162453-01; NCGC00162453-02; NCGC00162453-03; NCGC00162453-04; NCGC00162453-05; NCGC00162453-15; 3C10; AS-74315; HY-15144; M984; SMR004702883; A8183; SW219664-1; T2477; A25618; M02571; 880T196; Q425894; SR-05000013796; Q-201864; SR-05000013796-3; BRD-K68202742-001-04-1; BRD-K68202742-001-05-8; Trichostatin A, >=98% (HPLC), from Streptomyces sp.; Trichostatin A, Streptomyces sp. - CAS 58880-19-6; UNII-30RHG284Z4 component RTKIYFITIVXBLE-QEQCGCAPSA-N; Trichostatin A??, Vetec(TM) reagent grade, from Streptomyces sp., >=98%; (2E,4E,6R)-7-(4-(Dimethylamino)phen yl)-N-hydroxy-4,6-dimethyl-7-oxo-2,4-heptadienamid e; (6R)-N-Hydroxy-4,6-dimethyl-7-oxo-7-[4-(dimethylamino)phenyl]-2,4-heptadienamide; 7-[4-(Dimethylamino)phenyl]-N-hydroxy-4,6R-dimethyl-7-oxo-2E,4E-heptadienamide; 2,4-Heptadienamide, 7-[4-(dimethylamino)phenyl]-N-hydroxy-4,6-dimethyl-7-oxo-, (2E,4E,6R)- (9CI); 2,4-Heptadienamide, 7-[4-(dimethylamino)phenyl]-N-hydroxy-4,6-dimethyl-7-oxo-, [R-(E,E)]-; 2,4-Heptadienamide,7-[4-(dimethylamino)phenyl]-N-hydroxy-4,6-dimethyl-7-oxo-, (2E,4E,6R)-	.	Treatment with the HDAC inhibitor, trichostatin A (TSA), reduces YTHDC2 expression in Huh7 and in TNF-Alpha-stimulated hepatocytes.	24269672	.	.	.
REG00024	XENOBIOTIC00056	Olean-28,13Beta-lactam(B28)	.	.	.	B28 disrupts YTDFH1-GLS1 axis to induce ROS-dependent cell bioenergetics crisis and cell death which finally suppress PAAD cell growth, indicating that this synthesized olean-28,13Beta-lactam maybe a potent agent for PAAD intervention.	35366902	.	.	.
REG00025	XENOBIOTIC00057	Cholecalciferol	5280795	Vitamin D3; cholecalciferol; 67-97-0; Calciol; Colecalciferol; Oleovitamin D3; Ricketon; Arachitol; Trivitan; Deparal; Delsterol; Vigorsan; Ebivit; Activated 7-dehydrocholesterol; vitamin d-3; Colecalcipherol; Quintox; Colecalciferolum; Cholecalciferolum; (+)-Vitamin D3; D3-Vicotrat; D3-Vigantol; Vi-de-3-hydrosol; NEO Dohyfral D3; Vitinc Dan-Dee-3; 1406-16-2; Cholecalciferol, D3; Vi-De3; Provitina; Duphafral D3 1000; FeraCol; Delta-D; CC; CHEBI:28940; MFCD00078131; (1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol; NSC 375571; 9,10-Secocholesta-5,7,10(19)-trien-3-beta-ol; 7-Dehydrocholesterol activated; Micro-dee; 7-Dehydrocholesterol, Activated; VidDe-3-hydrosol; Vitamin D3 solution; NSC-375571; Colecalciferol (INN); Colecalciferol [INN]; NCGC00159331-02; Rampage; (3beta,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol; (5Z,7E)-(3S)-9,10-seco-5,7,10(19)-cholestatrien-3-ol; (5Z,7E)-(3S)-9,10-secocholesta-5,7,10(19)-trien-3-ol; DSSTox_CID_6294; DSSTox_RID_78090; DSSTox_GSID_26294; Vitamin D3 (Cholecalciferol); UNII-1C6V77QF41; 9,10-Seco(5Z,7E)-5,7,10(19)-cholestatrien-3beta-ol; Colecalciferolo; (3S,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol; Colecalciferolo [DCIT]; 9,10-Secocholesta-5(Z),7(E),10(19)-trien-3(.beta.)-ol; Vigantol Oil; (5e)-cholecalciferol; 22350-41-0; Colecalciferol D3; (1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(1R)-1,5-dimethylhexyl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylene-cyclohexanol; (S,Z)-3-(2-((1R,3aS,7aR,E)-7a-methyl-1-((R)-6-methylheptan-2-yl)octahydro-4H-inden-4-ylidene)ethylidene)-4-methylenecyclohexan-1-ol; Cyclohexanol, 3-[(2E)-2-[(1R,3aS,7aR)-1-[(1R)-1,5-dimethylhexyl]octahydro-7a-methyl-4H-inden-4-ylidene]ethylidene]-4-methylene-, (1S,3Z)-; Colecalciferolum [INN-Latin]; Vitamin D 3; 7-Dehydrocholestrol, activated; Irradiated 7-dehydrocholesterol; CCRIS 5813; CCRIS 6286; HSDB 820; 7-Dehydrocholesterol, irradiated; Vitamin D3 emulsifiable; EINECS 200-673-2; EINECS 215-797-2; EPA Pesticide Chemical Code 202901; Vitamin D3; Cholecalciferol; 1C6V77QF41; Devaron; Videkhol; NSC375571; Granuvit D3; DP-R206; CAS-67-97-0; Prestwick_63; Cholecalciferol D3; Cyclohexanol, 3-((2E)-2-((1R,3aS,7aR)-1-((1R)-1,5-dimethylhexyl)octahydro-7a-methyl-4H-inden-4-ylidene)ethylidene)-4-methylene-, (1S,3Z)-; Cholecalciferol [USP:BAN:JAN:ISO]; ()-Vitamin D3; 9,10-Seco(5Z,7E)-5,7,10(19)-cholestatrien-3-ol; Delta-D (TN); 9,10-Secocholesta-5,7,10(19)-trien-3-ol, (3beta,5Z,7E)-; Prestwick3_000429; bmse000507; UPCMLD-DP152; SCHEMBL3126; Vitamin d (cholecalciferol); CHEMBL1042; BSPBio_000418; Cholecalciferol; 67-97-0; Cholecalciferol (JP17/USP); BPBio1_000460; MEGxm0_000458; DTXSID6026294; UPCMLD-DP152:001; ACon1_001997; Vitamin d3 (as cholecalciferol); HMS2096E20; Vitamin d assay system suitability; Cholecalciferol, >=98% (HPLC); 9,10-Secocholestra-5,7,10(19)-trien-3-ol, (3beta,5Z,7E)-; Cholecalciferol, analytical standard; ZINC4474460; Tox21_111578; Tox21_202546; BDBM50030475; LMST03020001; s4063; AKOS015950641; AC-8884; CCG-268466; CS-1179; DB00169; SMP1_000068; AK R215 COMPONENT COLECALCIFEROL; AK-R215 COMPONENT COLECALCIFEROL; NCGC00091072-01; NCGC00159331-04; NCGC00260095-01; BS-42465; HY-15398; K119; Vitamin D3 10 microg/mL in Acetonitrile; 9,10-secocholesta-5,7,10-trien-3-ol; Cholecalciferol (D3), analytical standard; C05443; D00188; 9,10-Secocholesta-5,7,10(19)-trien-3-ol; Cholecalciferol, meets USP testing specifications; 078V131; 9,10-Secocholesta-5,7,10(19)-trien-3?-ol; Q139347; (5E,7E)-9,10-Secocholesta-5,7,10-trien-3-ol; Q-201931; 3-beta,Z,7E-9,10-Secocholestr-5,7,10(19)-trien-3-ol; Vitamin D3 solution, 100 mug/mL in ethanol, 97% (CP); (3beta,Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol; 9,10-Secocholesta-5,7,10(19)-trien-3-ol, (3b,5Z,7E)-; Cholecalciferol, European Pharmacopoeia (EP) Reference Standard; Colecalciferol, British Pharmacopoeia (BP) Reference Standard; Cholecalciferol, United States Pharmacopeia (USP) Reference Standard; Cholecalciferol for system suitability, European Pharmacopoeia (EP) Reference Standard; Vitamin D3 solution, 1 mg/mL in ethanol, ampule of 1 mL, certified reference material; (1S,3Z)-3-[(2E)-2-[7a-Methyl-1-(6-methylheptan-2-yl)-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol; Cholecalciferol (Vitamin D3), Pharmaceutical Secondary Standard; Certified Reference Material	.	vitamin D3 protects vascular endothelial cells from HCMV-induced apoptosis by reducing the elevated translation of MCU induced by HCMV through METTL3- and YTHDF3-dependent mechanisms via VDR/AMPK/METTL3 pathway.	35359726	.	.	.
REG00026	XENOBIOTIC00058	Ginsenoside Rh2	119307	Ginsenoside Rh2; 78214-33-2; 20(S)-Ginsenoside Rh2; Ginsenoside-Rh2; (20S)-ginsenoside Rh2; 20(S)-Ginsenoside; CHEBI:77147; 20S-Ginsenoside Rh2; UNII-0JU44A5KWG; 0JU44A5KWG; (2R,3R,4S,5S,6R)-2-[[(3S,5R,8R,9R,10R,12R,13R,14R,17S)-12-hydroxy-17-[(2S)-2-hydroxy-6-methylhept-5-en-2-yl]-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol; (20R)-Ginsenoside Rh2; (3beta,12beta)-12,20-dihydroxydammar-24-en-3-yl beta-D-glucopyranoside; C36H62O8; (20R)Ginsenoside Rh2; 20(S)-Ginsenoside-RH2; (S)Ginsenoside-Rh2; CHEMBL1783834; DTXSID70999457; 20(S)-Rh2; 112246-15-8; 67400-17-3; HY-N0605; BDBM50023457; Ginsenoside Rh2, analytical standard; MFCD00800712; s9023; s9036; ZINC72129809; AKOS037514675; CCG-270259; CCG-270261; CS-3835; AC-33940; Ginsenoside Rh2; 20(s)-Ginsenoside Rh2; X1143; C22128; 12,20-Dihydroxydammar-24-en-3-yl hexopyranoside; 214G332; Q-100827; Q27146703; 3beta-(beta-D-glucopyranosyloxy)dammar-24-ene-3beta,20beta-diol; beta-D-Glucopyranoside, (3beta,12beta)-12,20-dihydroxydammar-24-en-3-yl	.	Ginsenoside Rh2 reduces m6A RNA methylation via downregulating KIF26B expression in some cancer cells. KIF26B elevates m6A RNA methylation via enhancing ZC3H13/CBLL1 nuclear localization.	34764728	.	.	.
REG00029	XENOBIOTIC00060	Donepezil	3152	donepezil; 120014-06-4; Aricept; 2-((1-Benzylpiperidin-4-yl)methyl)-5,6-dimethoxy-2,3-dihydro-1H-inden-1-one; donepezilo; 2-[(1-benzyl-4-piperidyl)methyl]-5,6-dimethoxy-2,3-dihydroinden-1-one; 2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxy-2,3-dihydro-1H-inden-1-one; HSDB 7743; CHEMBL502; (S)-E2020 (free base); 142057-79-2; C24H29NO3; CHEBI:53289; 2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxy-2,3-dihydroinden-1-one; Donepezil [INN:BAN]; (RS)-2-[(1-BENZYL-4-PIPERIDYL)METHYL]-5,6-DIMETHOXYINDAN-1-ONE; 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-((1-(phenylmethyl)-4-piperidinyl)methyl)-; 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-; 142057-80-5; NSC 737535; NSC 758882; NCGC00167537-01; donepezilum; Domepezil; Donaz; Donepezil (INN); Donaz (TN); Spectrum_001664; Spectrum5_001662; SCHEMBL2149; Oprea1_188452; KBioSS_002144; BDBM8960; GTPL6599; SCHEMBL8265876; DTXSID8048317; KBio2_002144; KBio2_004712; KBio2_007280; AMY8939; CHEBI:145499; BCPP000253; HMS3886M11; BCP07590; MFCD00912833; s5073; STK003905; AKOS000277311; AKOS016842349; AC-6969; BCP9000622; CCG-268401; DB00843; MRF-0000323; HY-14566; I903; SBI-0206789.P001; D-797; FT-0601545; D07869; AB00640013-07; AB00640013-08; AB00640013_09; AB00640013_10; 014D064; Q415081; Q-100098; BRD-A49160188-003-04-4; Z1741977105; 2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one; (+/-)-2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxy-indan-1-one; 2-[(1-benzyl-4-piperidyl)methyl]- 5,6-dimethoxy-2,3-dihydroinden-1-one; 2,3-dihydro-5,6-dimethoxy-2 [[1-(phenyl methyl)-4-piperidinyl]methyl]-1H-inden-1-one; 2,3-dihydro-5,6-dimethoxy-2[[1-(phenyl methyl)-4-piperidinyl]methyl]-1H-inden-1-one; 5,6-dimethoxy-2-[[1-(phenylmethyl)piperidin-4-yl]methyl]-2,3-dihydroinden-1-one	.	Treatment of AIE-exposed adult rats with donepezil reversed both the dendritic spine adaptations and epigenetic modifications and expression of Fmr1.	29336496	.	.	.
REG00030	XENOBIOTIC00061	PMID30298385-Compound-scFv B7J	.	.	.	scFv B7J showed better binding to IGFBP2 at its carboxy terminal domain, blocked IGFBP2-cell surface association, reduced activity of matrix metalloprotease 2 in the conditioned medium of glioma cells and inhibited IGFBP2 induced migration and invasion of glioma cells.	30298385	.	.	.
REG00032	XENOBIOTIC00062	Lipopolysaccharide	.	PMID23160791-compound-LPS	.	CBLL1 was significantly up-regulated in the rat cerebral cortex after LPS administration, which suggested CBLL1 might participate in regulating neuronal biological function after neuroinflammation.	23160791	.	.	.